US20030055336A1 - Method and apparatus for measuring volume flow and area for a dynamic orifice - Google Patents

Method and apparatus for measuring volume flow and area for a dynamic orifice Download PDF

Info

Publication number
US20030055336A1
US20030055336A1 US09/467,165 US46716599A US2003055336A1 US 20030055336 A1 US20030055336 A1 US 20030055336A1 US 46716599 A US46716599 A US 46716599A US 2003055336 A1 US2003055336 A1 US 2003055336A1
Authority
US
United States
Prior art keywords
flow
velocity
power
orifice
volume
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US09/467,165
Other versions
US6544181B1 (en
Inventor
Thomas Buck
Robert Levine
Ronald Mucci
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Koninklijke Philips NV
General Hospital Corp
Original Assignee
Koninklijke Philips Electronics NV
General Hospital Corp
Agilent Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Koninklijke Philips Electronics NV, General Hospital Corp, Agilent Technologies Inc filed Critical Koninklijke Philips Electronics NV
Priority to US09/467,165 priority Critical patent/US6544181B1/en
Priority to PCT/US2000/004303 priority patent/WO2000051495A1/en
Priority to CA002362628A priority patent/CA2362628A1/en
Priority to EP00921337A priority patent/EP1161180A1/en
Assigned to AGILENT TECHNOLOGIES reassignment AGILENT TECHNOLOGIES ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MUCCI, RONALD A.
Assigned to THE GENERAL HOSPITAL CORPORATION A MASSACHUSETTS CORPORATION reassignment THE GENERAL HOSPITAL CORPORATION A MASSACHUSETTS CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BUCK, THOMAS
Assigned to GENERAL HOSPITAL CORPORATION, THE reassignment GENERAL HOSPITAL CORPORATION, THE ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LEVINE, ROBERT A.
Assigned to AGILENT TECHNOLOGIES INC. reassignment AGILENT TECHNOLOGIES INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HEWLETT-PACKARD COMPANY
Priority to US10/303,252 priority patent/US20030109785A1/en
Assigned to KONINKLIJKE PHILIPS ELECTRONICS N.V. reassignment KONINKLIJKE PHILIPS ELECTRONICS N.V. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: AGILENT TECHNOLOGIES INC.
Publication of US20030055336A1 publication Critical patent/US20030055336A1/en
Publication of US6544181B1 publication Critical patent/US6544181B1/en
Application granted granted Critical
Assigned to KONINKLIJKE PHILIPS ELECTRONICS N V reassignment KONINKLIJKE PHILIPS ELECTRONICS N V ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: AGILENT TECHNOLOGIES, INC.
Assigned to NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR reassignment NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR CONFIRMATORY LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: PARTNERS HEALTHCARE INNOVATION
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01SRADIO DIRECTION-FINDING; RADIO NAVIGATION; DETERMINING DISTANCE OR VELOCITY BY USE OF RADIO WAVES; LOCATING OR PRESENCE-DETECTING BY USE OF THE REFLECTION OR RERADIATION OF RADIO WAVES; ANALOGOUS ARRANGEMENTS USING OTHER WAVES
    • G01S15/00Systems using the reflection or reradiation of acoustic waves, e.g. sonar systems
    • G01S15/88Sonar systems specially adapted for specific applications
    • G01S15/89Sonar systems specially adapted for specific applications for mapping or imaging
    • G01S15/8906Short-range imaging systems; Acoustic microscope systems using pulse-echo techniques
    • G01S15/8979Combined Doppler and pulse-echo imaging systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00Diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/06Measuring blood flow
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00Diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/08Detecting organic movements or changes, e.g. tumours, cysts, swellings
    • A61B8/0883Detecting organic movements or changes, e.g. tumours, cysts, swellings for diagnosis of the heart
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00Diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/48Diagnostic techniques
    • A61B8/488Diagnostic techniques involving Doppler signals
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01FMEASURING VOLUME, VOLUME FLOW, MASS FLOW OR LIQUID LEVEL; METERING BY VOLUME
    • G01F1/00Measuring the volume flow or mass flow of fluid or fluent solid material wherein the fluid passes through a meter in a continuous flow
    • G01F1/66Measuring the volume flow or mass flow of fluid or fluent solid material wherein the fluid passes through a meter in a continuous flow by measuring frequency, phase shift or propagation time of electromagnetic or other waves, e.g. using ultrasonic flowmeters
    • G01F1/663Measuring the volume flow or mass flow of fluid or fluent solid material wherein the fluid passes through a meter in a continuous flow by measuring frequency, phase shift or propagation time of electromagnetic or other waves, e.g. using ultrasonic flowmeters by measuring Doppler frequency shift
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01SRADIO DIRECTION-FINDING; RADIO NAVIGATION; DETERMINING DISTANCE OR VELOCITY BY USE OF RADIO WAVES; LOCATING OR PRESENCE-DETECTING BY USE OF THE REFLECTION OR RERADIATION OF RADIO WAVES; ANALOGOUS ARRANGEMENTS USING OTHER WAVES
    • G01S7/00Details of systems according to groups G01S13/00, G01S15/00, G01S17/00
    • G01S7/52Details of systems according to groups G01S13/00, G01S15/00, G01S17/00 of systems according to group G01S15/00
    • G01S7/52017Details of systems according to groups G01S13/00, G01S15/00, G01S17/00 of systems according to group G01S15/00 particularly adapted to short-range imaging
    • G01S7/5205Means for monitoring or calibrating

Definitions

  • This invention relates to methods and apparatus for utilizing an ultrasonic pulsed wave Doppler signal to measure the instantaneous area of a dynamic orifice through which blood is passing and/or to measure instantaneous flow rate and flow volume of blood passing through such a dynamic orifice, and more particularly to such methods and apparatus which involves ensonifying a sample volume of blood flow exiting the orifice and identifying the region of such flow which is substantially laminar.
  • Ultrasound and more specifically the frequency range from 1 MHz to 5 MHz, is used for real-time imaging of the beating heart.
  • the efficiency of getting blood pumped through the body is dependent on a series of four one-way valves, each separating the two contracting chambers of the heart, which valves are prone to a variety of diseases, often times resulting in their inability to close properly.
  • Ultrasound, through the use of the Doppler concept is able to obtain information pertaining to blood flow within the heart and in the vicinity of the valves for diagnostic purposes, ultrasound having become the most important noninvasive diagnostic technique for cardiovascular disease.
  • valvular regurgitation that is the pathologic backflow of blood through a one-way valve when in the closed state, which is a serious, and at times life-threatening, condition common in virtually all acquired and congenital heart disease
  • the invention is by no means limited to this application, and some other applications will be discussed later.
  • Noninvasive procedures for quantification of regurgitant volume based on ultrasound do exist, but are subject to limitations that include: inaccurate diagnosis of lesion severity resulting from indirect measurements, multiple step procedures prone to error, and limiting assumptions about the flow associated with the lesion.
  • there is currently no truly satisfactory method for noninvasive quantification and even routine invasive methods, being costly and potentially risky, are only semi-quantitative.
  • Those invasive methods are based on direct catheterization of the heart that allows obtaining information about flow, volume, pressure, etc.
  • a potential solution is to use the backscattered acoustic power measurements of the received spectral Doppler signal as a measure of the area of flow. It is well known that each frequency component of the Doppler spectrum provides a measurement of acoustic power that is proportional to the volume of scatterers moving through the Doppler ultrasound beam at the velocity corresponding to the Doppler frequency. It follows that velocity times power, integrated over the entire velocity spectrum, should then be proportional to the volume flow rate Q• of all scatterers (mainly red blood cells) passing through the ultrasound beam, since the blood volume is related to the concentration of red blood cells by way of the hematocrit.
  • a method and apparatus for obtaining instantaneous area measurements for a dynamic orifice through which blood is flowing in at least one direction.
  • the technique involves ensonifying a thin sample volume of blood flow exiting the orifice, which volume is in a region of flow which is substantially laminar, with an ultrasonic pulsed Doppler signal; receiving backscattered signal from blood within the sample volume; forming a power-velocity spectrum from the received backscattered signal; and forming the power integral of the laminar flow from the spectrum, this power integral being proportional to an instantaneous cross-sectional area of the orifice.
  • a time profile of instantaneous areas of flow for the orifice may be obtained by repetitively performing the laminar flow power integral measurement for successive time intervals.
  • the portion of laminar flow in the power velocity spectrum is preferably determined.
  • the sample volume is at the vena contracta of flow exiting the orifice.
  • the vena contracta is the smallest cross-sectional area traversed by flow just beyond the orifice, it being found that flow is substantially laminar at the vena contracta, this vena contracta being the region where entrainment of flow turbulence is at its minimum.
  • the ultrasonic Doppler signal is electronically steered and focused to the vena contracta and is preferably wide enough so as to fully ensonify the vena contracta.
  • the electronic steering and focusing may be performed by moving the ultrasound signal through blood flow exiting the orifice, and detecting a Doppler spectral display and/or audio output, the signal being at the vena contracta when the Doppler signal consists primarily of laminar flow.
  • the power velocity spectrum is preferably smoothed to eliminate the effects of any aberrations therein, and the velocity for peak power is determined for each time interval.
  • a lower velocity of laminar flow is then determined as being a selected velocity, for example the maximum velocity, which is less than the velocity at peak power where the power is at a selected percentage of the peak power, and an upper velocity of laminar flow is determined which is a selected velocity, for example a minimum velocity, greater than the velocity at peak power where the power has dropped to a specified percentage of the peak power.
  • the percentage of peak power may be from approximately 30% to approximately 60%, with approximately 50% or ⁇ 3 db being the percentage of peak power for an illustrative embodiment.
  • the flow may for example be regurgitant flow through a faulty heart valve, the orifice area being that of lesions in the heart valve permitting the regurgitant flow.
  • the invention also involves a technique for obtaining instantaneous flow rates of blood passing through a dynamic orifice in at least one direction, which technique includes ensonifying a thin volume of blood flow exiting the orifice, which volume is in a region of flow which is substantially laminar, with an ultrasonic pulsed wave Doppler signal which fully encompasses the cross-sectional area of the volume where flow is substantially laminar; receiving backscattered signal from blood within the pulsed wave Doppler sample volume; forming a power-velocity spectrum from received backscattered signal; and forming the instantaneous power-velocity integral (PVI) from the laminar flow of the spectrum.
  • a technique for obtaining instantaneous flow rates of blood passing through a dynamic orifice in at least one direction which technique includes ensonifying a thin volume of blood flow exiting the orifice, which volume is in a region of flow which is substantially laminar, with an ultrasonic pulsed wave Doppler signal which fully encompasses the cross-
  • a pulsed wave Doppler signal such as high-PRF Doppler, capable of representing the full range of velocity, is preferred.
  • a time profile of instantaneous flow rates for the orifice may be obtained by calculating the instantaneous power-velocity integrals for successive time intervals.
  • the thin sample volume is preferably at the vena contracta of the flow exiting the orifice, with electronic steering preferably being performed on the ultrasonic signal to steer and focus it to the vena contracta and is wide enough so as to fully ensonify the vena contracta.
  • the electronic steering and focusing may be performed by scanning the ultrasound signal through blood flow exiting the orifice and detecting at least one of Doppler spectral display and audio output, the signal being at the vena contracta when the output of the detecting step identifies laminar flow.
  • Flow at non-laminar velocities may be eliminated from the PVI determination in the manner described above.
  • the flow may for example be regurgitant flow through a faulty heart valve, the orifice area being that of lesions in the heart valve permitting regurgitant flow.
  • calibration may include detecting backscattered Doppler ultrasound power from the reference beam when the valve is open for forward flow.
  • the invention involves a technique for obtaining flow volume for blood passing through a dynamic orifice in at least one direction, which technique includes ensonifying a thin volume of blood flow exiting the orifice, which volume is in a region of flow which is substantially laminar, with an ultrasonic pulsed wave Doppler signal which fully encompasses the cross-sectional area of the volume where flow is substantially laminar; receiving backscattered signal from blood within the pulsed wave Doppler sample volume; forming a power-velocity spectrum from received backscattered signal; and forming the instantaneous power-velocity integral (PVI) from the laminar flow portion of the spectrum and the profile of the instantaneous flow rates.
  • a technique for obtaining flow volume for blood passing through a dynamic orifice in at least one direction which technique includes ensonifying a thin volume of blood flow exiting the orifice, which volume is in a region of flow which is substantially laminar, with an ultrasonic pulsed wave Doppler signal which fully encompasses
  • the flow volume is obtained from the time integral of the instantaneous flow rate (PVTI).
  • a pulsed wave Doppler signal such as high-PRF Doppler
  • the thin sample volume is preferably at the vena contracta of the flow exiting the orifice
  • the technique preferably includes electronic steering and focusing the ultrasonic signal to vena contracta, and non-laminar velocities being removed from the calculations using techniques previously discussed.
  • the ultrasound signal is preferably wide enough so as to fully ensonify the vena contracta.
  • the flow may for example be regurgitant flow through a faulty heart valve, the orifice area being that of lesions in the heart valve permitting regurgitant flow. Where the flow is regurgitant flow through a faulty heart valve, detected forward and regurgitant flow may be combined to obtain a measure of regurgitant fraction.
  • calibration may include detecting backscattered Doppler ultrasound power from the reference beam when the valve is open for forward flow.
  • FIG. 1A is a representation of the anatomy and physiology of the human heart, FIG. 1B and FIG. 1C being enlarged views for a portion of the heart shown in FIG. 1A during diastolic and systolic phases, respectively;
  • FIG. 2A is an illustration of data acquisition using an ultrasonic transducer in accordance with the teachings of this invention.
  • FIG. 2B is an ultrasonic display for two-dimensional image mode
  • FIG. 2C is an exemplary ultrasonic display at the vena contracta for Doppler mode
  • FIG. 3 is a representation of the anatomy for a regurgitant jet
  • FIG. 4B is a diagrammatic representation of an exemplary velocity distribution across an area of flow
  • FIG. 4C is a plot of backscattered power versus frequency from the received Doppler spectrum shown in FIG. 4B
  • FIG. 4D is a plot illustrating the conversion of power and frequency to display video intensity and velocity
  • FIGS. 4E and 4F are exemplary displays of actual flow measurements (velocity vs. time) by Doppler for in vitro steady flow and in vivo parabolic flow, respectively;
  • FIG. 5 is a diagrammatic illustration of the principle of volume flow rate calculation over an area of flow for a spectrum of three different flow velocities
  • FIG. 6 is a diagrammatic representation illustrating the proportionality of backscattered Doppler power to a sonified volume of blood
  • FIG. 7 is a diagram illustrating the independence of the power-velocity spectrum from the distribution of velocities across the flow CSA;
  • FIG. 8 is a diagrammatic representation illustrating calibration using a broad measurement beam and a narrow reference beam
  • FIGS. 9 A- 9 D are a high-PRF Doppler signal, an enlarged sector of the signal shown in FIG. 9A, a PI plot and a PVI plot, respectively for an exemplary orifice and flow profile;
  • FIG. 10 is a schematic representation of the flow phantom used for in vitro experiments for validation the teaching of this invention.
  • FIGS. 11A and 11B are plots of various results for PI achieved in an in vitro study of this invention.
  • FIG. 12 is a plot of various calculated and calibrated PVI values versus actual flow rates for in vitro experiments involving the teaching of this invention.
  • FIG. 13 is a plot of calculated and calibrated PVTI values versus actual regurgitant flow volumes for exemplary in vitro experiments involving the teaching of this invention
  • FIG. 14 is a schematic diagram of an in vivo animal model used in performing in vivo experiments involving this invention.
  • FIG. 15 is a plot of calculated and calibrated mitral regurgitant stroke volume (MRSV) versus actual values of MRSV for in vivo animal experiments;
  • FIGS. 16 A- 16 C are illustrative Doppler spectra for a patient with functional mitral regurgitation
  • FIG. 17 is a plot of calculated and calibrated mitral regurgitant stroke volume (MRSV) versus independent reference values of MRSV in patient studies;
  • FIG. 18A is a schematic structure presentation, and FIG. 18B are plots useful in conjunction with Appendix A for describing the principles of pulse Doppler for blood velocity measurement;
  • FIG. 19 is a plot useful in conjunction with Appendix B for illustrating beam properties, and in particular the use of a smaller aperture to produce a larger beam CSA.
  • FIG. 20 is a plot useful in conjunction with Appendix C for understanding broadening of the power-velocity spectrum of laminar flow.
  • FIG. 1A the heart is shown as having four chambers—left and right ventricle (LV and RV) and left and right atrium (LA and RA). These chambers are connected by four one-way valves, the mitral (MV), aortic (AV), tricuspid (TV) and pulmonary (PV) valves. There are also various vessels going in and out of the heart.
  • the arrows in FIG. 1A indicate the direction of the blood where the venous return enters the right heart via the right atrium and is pumped by the right ventricle via pulmonary valve and pulmonary artery to the left and right lung.
  • the blood After oxygenation in the lungs, the blood re-enters the heart via the pulmonary veins and flows to the left ventricle via the left atrium and the mitral valve.
  • the left ventricle as the strongest contracting chamber, pumps the oxygenated blood to the entire body via the aortic valve and the aorta, thereby creating the systemic blood pressure.
  • FIGS. 1B and 1C indicate the direction of blood flow during the two phases of one heart cycle, diastole where the left ventricle relaxes to refill with blood from the left atrium, and systole where the left ventricle contracts to eject the blood to the aorta.
  • FIG. 1C shows the pathologic regurgitant flow when the mitral valve closes incompletely during systole.
  • FIG. 2A illustrates the use of an ultrasonic transducer to acquire data on the heart.
  • the ultrasonic transducer is positioned onto the outer chest wall of the patient, and its beam is oriented to the region of flow.
  • a high-PRF Doppler sample volume is depicted, which is located in the vena contracta which, as indicated previously, is the narrowest portion of the jet.
  • FIG. 2B shows how a two-dimensional image plane intersecting the heart is used to navigate the Doppler beam so as to place the sample volume at the vena contracta, which is at the white arrow in FIG. 2B.
  • the system may be changed to pulsed Doppler mode to register the Doppler signal as depicted in FIG. 2C.
  • the velocities are displayed below a baseline of 0, indicating that the flow is away from the transducer passing from the left ventricle through the diseased mitral valve back to the left atrium.
  • FIG. 3 is a diagram illustrating the anatomy of a regurgitant jet, illustrating the vena contracta, the core of laminar flow, and the regions of entrainment of fluid and turbulence.
  • the vena contracta is shown as the narrowest portion of the regurgitant jet just below the orifice where velocities are highest and flow is larninar across the jet prior to entrainment of fluid and turbulence.
  • the figure also indicates the Doppler beam and the sample volume located at the vena contracta.
  • Cross-sectional views at the right indicate the laminar flow at the vena contracta and the turbulent flow beyond the vena contracta.
  • the ultrasound system for Doppler operation, the ultrasound system, through the use of a hand-held transducer, transmits an ultrasound beam that is electronically steered and focused. It is the backscattered ultrasound that provides the diagnostic information, the ultrasound energy within the beam backscattered as it propagates within the body. To acquire the backscattered signal, the ultrasound system operates in ‘reverse’ using the same transducer to receive the backscattered energy, again with electronic steering and focusing.
  • the spectral Doppler power is proportional to the volume of backscatterers on a frequency basis. This power spectrum is mapped to a vertical line of display intensity. The spectrum is computed and displayed continually and in real-time as depicted in FIGS. 4E and 4F.
  • Parabolic flow (FIG. 4F) pertains to the shape of the narrow-band velocity trace over time from an in vivo pulsatile flow through a mitral valve regurgitant orifice during systolic left ventricular contraction in a patient.
  • power at f 2 is twice as large as at f 1 or f 3 because the area of V 2 is twice as large as of V 1 and V 3 .
  • the power spectrum of the demodulated received waveform is computed using an FFT algorithm and analyzed by the ultrasound imaging system.
  • the analysis of the received Doppler signal provides two important components; the Doppler frequency and the corresponding backscattered signal strength (acoustic power).
  • f D denotes the Doppler frequency of the backscattered signal
  • f denotes the transmit frequency of the ultrasound
  • c denotes the speed of propagation of sound within the medium, (the approximate speed of sound in water is 1470 m/sec, in soft tissue 1540 m/sec and in bone 4800 m/sec)
  • V SC denotes the velocity of the scattering object, presumably blood
  • denotes the angle between the direction of the ultrasound beam and the direction of blood velocity.
  • the spectral content of the backscattered Doppler signal is determined.
  • the spectral bins of sufficient amplitude not only indicate blood flow at velocities as determined by Eq. 1, but also backscattered power is proportional to the amount of blood flowing at the corresponding velocity (FIG. 4C).
  • FFT fast Fourier transform
  • a lumen is defined, as a bounded cross-sectional planar area denoted by the vector A l ⁇ of direction perpendicular to the planar surface, through which flows an incompressible fluid with directional velocity function v ⁇ (x, y, t) across the area of flow at instantaneous time t.
  • the incremental flow ⁇ Q•(x, y, t) passing through the differential area ⁇ A ⁇ (x, y) at time t is given by v ⁇ (x, y, t)• ⁇ A ⁇ (x, y) where • denotes the dot product operation of two direction vectors.
  • the dot product of two vectors a and b is defined as the product of their magnitudes times the cosine of the angle between them.
  • the Doppler spectrum from a sample volume applied to such a vessel only contains the signal from the vessel flow
  • the Doppler spectrum from the sample volume of a regurgitant jet at the level of the vena contracta contains signal from laminar and turbulent flow. This requires the identification of the laminar portion of the Doppler spectrum and the use only of this portion in the calculation of the measurements.
  • the operator of the system initially utilizes a standard ultrasonic beam control, such as a joy stick or tracker ball, to adjust the beam as shown in FIGS. 2A and 2B to pass through the mitral valve or other valve of interest.
  • a standard ultrasonic beam control such as a joy stick or tracker ball
  • the depth for imaging is then adjusted on the machine in standard fashion so as to be directly adjacent a regurgitant side of the valve at the vena contracta. All this is done with the ultrasound system in image mode as shown in FIG. 2B, the desired imaging spot being generally at the bright dot being pointed to by the arrow.
  • the beam is focused at substantially the desired point, but may not be exactly centered with the flow to be measured.
  • the ultrasound system is switched to Doppler mode, resulting in a display such as that shown in FIG. 2C, illustrating velocity versus time.
  • FIG. 9A is an alternative image.
  • the bright signals in the low velocity area on these displays, for example under 100, is generally tissue noise, turbulent flow, and the like, while the bright higher frequency band on the outside of each of these images is generally from laminar flow.
  • the narrowness and cleanness of this bright narrow-band spectrum will be optimized.
  • the backscattered signal is smoothed utilizing a standard averaging or smoothing technique.
  • the operator looks at the Doppler mode image and fine tunes transducer position and/or image depth until the “cleanest” observed image is obtained.
  • the smoothed backscattered signal may be converted to audio, the signal from the vena contracta being the cleanest tone involving the fewest frequencies.
  • this fine tuning could be done automatically, with for example the beam position and depth being slightly adjusted through a small range, and for example an audio signal being monitored to provide a feedback signal for controlling the beam in a direction resulting in the cleanest audio output. This could be done first for position and then for depth, or the two could be done simultaneously in accordance with a selected feedback controlled scanning algorithm.
  • FIGS. 9A and 9B are enlarged images of the portion of FIG.
  • the backscattered signal contains a number of velocities, the power at a given velocity for the time t i being indicated by the brightness of the image for the velocity V i at the given time, a brighter image indicating more power.
  • V low the lower velocity of laminar flow
  • V R the velocity for peak power
  • the power is a specified percentage of peak power. This percentage may, for example, be in an approximate range of 30% to 60% of peak power depending on application, being 50% or ⁇ 3 DB for an illustrative embodiment.
  • V high the upper velocity of laminar flow is determined by finding the minimum velocity which is greater than the velocity V R of peak power where the power is the specified percentage of the peak power. While the specified percentage of peak power need not be the same for determining V low and V high , these percentages are the same for an illustrative embodiment and would normally be the same.
  • V low and V high are determined for a given time t I , only backscattered radiation having a velocity falling within this range is utilized and performing the various calculations, thus assuring that only laminar flow at the vena contracta is being utilized for these calculations.
  • Pulse-wave (PW) Doppler is used since, as described in Appendix A, this allows a range gate to be set which in turn controls the thickness of the interrogated volume.
  • PW Doppler a relatively short pulse is transmitted and the sample volume thickness is controlled by receiving and analyzing the backscattered ultrasound for a relatively short interval of time.
  • the total backscattered acoustic power from such a Doppler sample volume is linearly proportional to the sonified blood volume, where the proportionality factor is given by the backscattering coefficient that is related to the number of independent scatterers, mainly red blood cells (erythrocytes), in this volume.
  • the backscattered power is linearly proportional to the cross-sectional area (CSA) of the flow within the lumen projected onto the surface of the sample volume of the sonifying ultrasound beam as shown in FIG. 6.
  • CSA cross-sectional area
  • the thickness of the sample volume is thin and constant, that the concentration of scatterers (hematocrit) is constant, and that the beam encompasses the entire CSA of flow.
  • the total backscattered power from a jet with a CSA of 1.0 cm 2 would be twice as much as from a jet with a jet CSA of 0.5 cm 2 .
  • This approach does not require the existence of a lumen nor the explicit determination of the velocity distribution over the cross-sectional area of the vena contracta. Rather, the Doppler beam encompassing the entire area of flow, effectively integrates the contribution of all scatterers at each velocity of laminar flow regardless of the velocity profile (FIG. 7). That is, in the Doppler modality the backscattered acoustic signal power increases linearly by the number of scatterers traveling at the same velocity, independent of their individual locations within the jet CSA and independent of their individual locations within the sample volume.
  • the Doppler modality requires the elimination of signal backscattered from tissue prior to the calculation of the power spectrum, since the backscattered power of tissue can be 100 to 1000 times greater than the power backscattered by blood.
  • a high-pass filtering process referred to as a wall filter, that eliminates Doppler signals backscattered from low velocity targets such as tissue.
  • the backscattered power is independent of velocity, only the backscattered power of blood flow above the cutoff velocity of the wall filter is measured. From this it also becomes clear that blood within the sample volume that is not flowing, such as that external to the vena contracta, does not contribute to the power spectrum and therefore does not contribute to the area and associated flow measurement.
  • the spectral Doppler power associated with a Doppler frequency is linearly proportional to the cross-sectional area of scatterers traveling at the velocity v, corresponding to the Doppler frequency.
  • the power associated with a given frequency (or velocity) times the velocity is equivalent to the area times the velocity, which in turn provides a measure of the component of flow attributable to scatterers of the specified velocity. If this calculation of power times velocity is integrated for each component of the Doppler spectrum, an estimate proportional to the total instantaneous flow passing through the vena contracta, denoted Q• v (t), can be obtained. That is, Q ⁇ ( t ) ⁇ vel ⁇ P ⁇ ( v ) ⁇ v ⁇ ⁇ ⁇ v ( 5 )
  • the Doppler power-velocity principle also indicates that the backscattered power integrated over the velocity spectrum at the vena contracta is proportional to the cross-sectional area of the vena contracta, regardless of flow rate.
  • the proportionality between power and CSA depends mainly on attenuation and the backscattering coefficient, which is a nonlinear function of hematocrit.
  • the calibration technique described later takes this into account by comparing measured power over the entire sample volume with that in a small reference beam of known CSA.
  • Procedures required in practicing the teaching of this invention included: 1) generation of a Doppler beam sufficiently wide to encompass the cross-sectional area of the vena contracta of a regurgitant jet, and 2) a method of calibration to compensate for variations in attenuation and the backscattering coefficient. The following is a brief description of each procedure:
  • the full 1.2 cm by 2.0 cm transducer aperture of the transducer used produces a beam having a cross-sectional area of approximately 3.1 mm in elevation by 5.2 mm in the lateral dimension at a 10 cm depth, based on defining the border of the beam CSA by where the sensitivity of the transducer drops to the half-maximal power or ⁇ 3 db.
  • a broader measurement was produced based on the principle that the smaller the transducer aperture, the broader the distal beam (see FIG. 8).
  • the aperture for the left measurement beam was diminished with the application of a Tyvek (Dupont) mask over the transducer face.
  • the invention only requires that a proportionality exist between PVI and flow, it is necessary to calibrate the system in order to obtain absolute measurements of area and flow rate in a clinically useful manner. That is, in part because the power measurements obtained by the ultrasound system are unitless, and in part because for the same blood volume, Doppler power measurements will vary among patients due to differences in attenuation and backscattering coefficients (related to patient hematocrit).
  • the Doppler measurements in each individual can be calibrated with a narrow reference beam that fits within an area of flow in the vicinity of the vena contracta (right beam FIG. 8). This beam is used to establish the ratio between reference power integral PI ref and the known CSA of the reference beam at that depth, CSA ref .
  • the flow CSA at the vena contracta is four times the known CSA of the reference beam. Since the area of the reference beam is known, the calibrated power measurement provides an estimate of the flow CSA at the vena contracta.
  • the technique used to widen the beam also reduced the transmit power and receive sensitivity due to the reduced aperture size. That is, the power measured by the broader beam is less than that of the reference beam for the same cross-sectional area of flow, assuming the cross-sectional area of flow is contained within both the narrow reference and broader measurement beam (Appendix B).
  • CF denotes the correction factor accounting for aperture reduction.
  • This correction factor was determined in vitro by comparing the backscattered power for both beams for flow through an orifice smaller in cross-sectional area than both beam-widths (0.07 cm 2 ; Appendix B). In this case, as the transducer aperture was reduced to 11 mm in diameter, the Doppler power measurement decreased by a factor of 5.0, so that the power measurement must be multiplied by a correction factor of 5.0 before it can be compared with the power of the reference beam to determine the cross-sectional area of the jet at the vena contract.
  • the backscattered power from the narrow reference beam alternatively can be captured in the filling phase of the mitral valve when the valve is wide open (FIG. 1B); that is because the ratio only requires backscattered power from the flow region of interest independent from velocity.
  • the calibration procedure may be simplified by having the two required beams, the narrow reference and the broad measurement beam, generated simultaneously. This is done by taking advantage of a modern digital ultrasound system's capability, the basic principle being as follows: On transmit, the transducer generates a broad and relatively uniform beam that sonifies the entire area of flow as discussed in Appendix D. On receive, the two required beams, the narrow reference and the broad measurement beam, are generated simultaneously by the connection of the transducer elements to two independent digital beam-forming processors. Thus, the Doppler signal information can be acquired and calibrated in a single cardiac phase, thereby eliminating the need to perform a separate calibration operation.
  • the regurgitant fraction which is the ratio of regurgitant flow volume to forward flow volume through the valve, can be measured using this non-invasive approach. Measurements are obtained of the regurgitant flow volume and the forward flow volume associated with the valve. Since the measurement of regurgitant fraction consists of the ratio of the two measurements, calibration is not necessary.
  • a relatively thin sample volume of axial gate length of 0.35 cm was used and, to prevent signal suppression at low flow rates, a low velocity filter (wall filter) cut-off of 200 Hz ( ⁇ 8 cm/s) was selected.
  • Settings of compress and reject, transmit power, receive gain, depth, and velocity range were kept constant in the entire in vitro series as well as within each patient and animal to allow comparison of returned signals during each series.
  • Doppler spectra were stored digitally, converted off-line to ASCII format and analyzed with MATLAB software (Version 5.1, MathWorks, Natick, Mass.). Power and power times velocity were then integrated over all velocities in the velocity spectrum corresponding to laminar flow in the vena contracta (FIG. 9).
  • PI power integral
  • PVI power-velocity integral
  • PI power-velocity time integral
  • a flow phantom was built to simulate the condition of regurgitant flow at the mitral valve.
  • the flow phantom (FIG. 10) consisted of a variable diameter orifice located 10 cm from the ultrasound transducer acoustic window (typical distance in vivo of a mitral regurgitant orifice from the transducer placed on the chest surface; see FIG. 2A), with flow passing from a large cylindrical chamber (5.7 cm diameter; mimicking the LV) to an unconfined receiving chamber (mimicking the LA).
  • Circular orifice areas of 0.2, 0.5 and 0.8 cm 2 were studied at 5 steady flow rates from 20 to 60 ml/s produced by a piston pump (modified Mark IV Powerinjector, Medrad, Inc., Indianola, Pa.) that minimized cavitation, as opposed to impeller-based pumps which were found to produce microairbubbles by cavitation, and with 6 parabolic pulses of regurgitant stroke volumes of 20 to 70 ml (4 different-shaped flow profiles for each stroke volume) produced by syringe injections.
  • Initial studies with outdated blood or blood analogs containing surfactant produced microairbubbles due to cavitation as fluid encountered the pressure drop at the orifice.
  • ROA regurgitant orifice area
  • c cal (reference beam CSA/reference beam PI) times the correction factor (CF) needed to account for the decrease in power related to aperture reduction (see Eq. 9).
  • the correction factor CF and the reference beam CSA are determined in vitro; only reference and measurement beam PI need to be measured in vivo.
  • reference beam CSA was 0.125 cm 2 and CF was 63 (Appendix B, 7 mm aperture). With calibration, PI values were converted to regurgitant orifice area (ROA) and correlated and agreed well to actual ROA less than 0.8 cm 2 (FIG.
  • ROA regurgitant orifice area
  • MRSV mitral regurgitant flow volume
  • FIG. 17 shows an example of such a velocity spectrum in a patient with functional mitral regurgitation.
  • the power integral has early and late systolic peaks and mid-systolic decrease, which is the recognized pattern for regurgitant orifice area in such patients since the two valve leaflets are pushed together in mid-systole by the peak LV pressure, which decreases the orifice area.
  • the innovative approach of this invention is based on the integral of backscattered acoustic power, which, in principle, provides a measure of flow cross-sectional area.
  • the basic physics of flow and ultrasound indicate the integral of Doppler power times velocity can measure flow rate and flow volume
  • investigators have felt this principle could not be applied to regurgitant pathologic jets comprised of high-velocity flow in the human heart because backscattered power is variably increased by turbulence and entrainment of fluid. For that reason previous studies using Doppler power evaluated only flows that were restricted to a conduit (tube, large vessel, or ventricular outflow tract) and therefore considered laminar.
  • This invention demonstrates that this limitation can be overcome by integrating power times velocity in the narrow velocity spectrum obtained from flow passing through a thin sample volume placed in the vena contracta, that is, at the origin of the regurgitant jet, where flow is mostly laminar since turbulence has not yet developed.
  • regurgitant flow rate and volume can be measured using only the backscattered power and velocity information as obtained by ultrasound Doppler. Because, integrating backscattered power times velocity over the Doppler spectrum automatically contains a measure of the flow cross-sectional area due to the proportionality of backscattered power to flow area, this approach overcomes the limitations of most techniques that require a separate area measurement. Second, the thin Doppler sample volume can be placed directly at the lesion where regurgitant flow occurs, making possible the most direct and therefore accurate measurement of regurgitant flow area and flow volume. Third, with this approach there are no simplifying assumptions about the velocity distribution across the flow area, because the Doppler beam effectively integrates all incremental areas of different flow rates.
  • Future systems may be developed which simplify the procedure for routine clinical application.
  • the described system has an ultrasound transducer capable of creating a broad and uniform measurement beam and a narrow reference beam for calibration purposes. Thereafter a manual, partially automated or fully automated analysis of the Doppler signal is performed by the system, identifying the narrow Doppler spectrum associated with laminar flow in the vena contracta and calculating PI, PVI, and PVTI. Finally, the results of the measurement beam are calibrated taking into account transmit power, receive gain, and other relevant system settings, thereby producing and displaying measurements of diagnostic importance such as peak cross-sectional area of flow, mean cross-sectional area of flow, peak flow rate, mean flow rate, stroke volume and regurgitant fraction.
  • this PVI approach could be used to obtain regurgitant fraction as the ratio of regurgitant flow volume to normal forward flow volume; this would require a beam encompassing the cross-sectional area of forward flow when the valve is open.
  • the beauty of this approach would be that both regurgitant and forward volume could be determined from the same sample volume.
  • the PVI concept can overcome the limitations of existing techniques that are invasive, costly, and inaccurate and has the potential to replace them.

Abstract

Techniques are provided for obtaining selected instantaneous area measurements for a dynamic orifice through which blood is flowing in at least one direction, for obtaining instantaneous flow rates of blood passing through such a dynamic orifice and for obtaining flow volume for blood passing through a dynamic orifice. All of these techniques involve ensonifying a thin sample volume of blood flow exiting at the orifice, which volume is in a region of flow which is substantially laminar, such region normally being the vena contracta for the orifice, with an ultrasonic pulsed Doppler signal, receiving backscattered signal from blood within the sample volume and forming a power-velocity spectrum from the received backscattered signal. Techniques are disclosed for assuring that only laminar flow is looked at in forming the power-velocity spectrum. To obtain instantaneous area measurements, the power integral of laminar flow from the spectrum is formed, this power integral being proportional to an instantaneous cross-sectional area of the orifice. For instantaneous flow rates, the instantaneous power-velocity integral is formed from the laminar flow of the spectrum, while flow volume is obtained from the timed integral of the instantaneous flow rate.

Description

    RELATED APPLICATION
  • This application claims priority from provisional application Serial No. 60/122,926, filed Mar. 5, 1999, the contents of which are incorporated herein by reference.[0001]
  • GOVERNMENT RIGHTS
  • [0002] Work in this invention was supported in part by Grants HL38176 and HL57302 from the National Institute of Health, Bethesda, Md. and BU 1097/-1 from the Deutsche Forschungsgemeinschaft, Bonn, Germany.
  • FIELD OF THE INVENTION
  • This invention relates to methods and apparatus for utilizing an ultrasonic pulsed wave Doppler signal to measure the instantaneous area of a dynamic orifice through which blood is passing and/or to measure instantaneous flow rate and flow volume of blood passing through such a dynamic orifice, and more particularly to such methods and apparatus which involves ensonifying a sample volume of blood flow exiting the orifice and identifying the region of such flow which is substantially laminar. [0003]
  • BACKGROUND OF THE INVENTION
  • Ultrasound, and more specifically the frequency range from 1 MHz to 5 MHz, is used for real-time imaging of the beating heart. In the human heart, the efficiency of getting blood pumped through the body is dependent on a series of four one-way valves, each separating the two contracting chambers of the heart, which valves are prone to a variety of diseases, often times resulting in their inability to close properly. Ultrasound, through the use of the Doppler concept, is able to obtain information pertaining to blood flow within the heart and in the vicinity of the valves for diagnostic purposes, ultrasound having become the most important noninvasive diagnostic technique for cardiovascular disease. However, the use of noninvasive ultrasound techniques to quantify pathologic backflow associated with valvular heart disease, other cardiac pathologies such as inter-septal shunting and other blood flows through dynamic orifices of unknown area has been an elusive medical goal for many years. [0004]
  • While for the purpose of this discussion, focus will be on valvular regurgitation, that is the pathologic backflow of blood through a one-way valve when in the closed state, which is a serious, and at times life-threatening, condition common in virtually all acquired and congenital heart disease, the invention is by no means limited to this application, and some other applications will be discussed later. [0005]
  • Leakage of one or more valves is caused by various diseases which prevent the leaflets of the valve from closing sufficiently, thereby creating a lesion called a regurgitant orifice. There is a need to accurately measure the volume of regurgitation (reverse blood flow) as a guide both to diagnosis and to therapy, especially now that valve repair techniques allow interventions to be considered earlier in the disease before dilation of the chambers (atria and ventricles) and subsequent heart failure occur. Current uncertainties regarding the natural history of the valve disease and the optimal timing of surgery are compounded by a limited ability to measure the basic lesion. Noninvasive procedures for quantification of regurgitant volume based on ultrasound do exist, but are subject to limitations that include: inaccurate diagnosis of lesion severity resulting from indirect measurements, multiple step procedures prone to error, and limiting assumptions about the flow associated with the lesion. In fact, there is currently no truly satisfactory method for noninvasive quantification, and even routine invasive methods, being costly and potentially risky, are only semi-quantitative. Those invasive methods are based on direct catheterization of the heart that allows obtaining information about flow, volume, pressure, etc. [0006]
  • The fundamental problem in using noninvasive ultrasound is that Doppler measures the velocity, not the desired volume, of regurgitant blood flow. Therefore, in order to determine volume of blood passing through an orifice, for example the regurgitant orifice of a diseased heart valve, the area of flow, also referred to as the effective orifice area, has to be known. All methods to date have failed to measure the effective orifice area accurately because of the complex shape and dynamic changes of this area throughout the period of flow. [0007]
  • A potential solution is to use the backscattered acoustic power measurements of the received spectral Doppler signal as a measure of the area of flow. It is well known that each frequency component of the Doppler spectrum provides a measurement of acoustic power that is proportional to the volume of scatterers moving through the Doppler ultrasound beam at the velocity corresponding to the Doppler frequency. It follows that velocity times power, integrated over the entire velocity spectrum, should then be proportional to the volume flow rate Q• of all scatterers (mainly red blood cells) passing through the ultrasound beam, since the blood volume is related to the concentration of red blood cells by way of the hematocrit. [0008]
  • This Doppler power principle holds only for laminar flow and was applied to flow in vessels but it has long been assumed that it cannot be applied to regurgitant jets, that is jets comprised of the regurgitant flow of blood, since the assumption is that the jet contains turbulent eddies which are believed to increase the backscattered power. In addition, entrainment of blood into the jet can contribute to the overestimation of the actual flow through the orifice. [0009]
  • While the problems of measuring flow volume and/or orifice area for a dynamic orifice through which blood flows is a particular problem when measuring regurgitant flow through a heart valve, similar problems arise in measuring valvular stenosis, septal defects with shunt flow, and peripheral vascular disease with vessel obstruction. In these and other applications, a need exists for an improved noninvasive method and apparatus for measuring flow volume and/or orifice area for a dynamic orifice having blood flow therethrough, which technique does not suffer the limitations discussed above for existing methodologies. [0010]
  • SUMMARY OF THE INVENTION
  • In accordance with the above, a method and apparatus are provided for obtaining instantaneous area measurements for a dynamic orifice through which blood is flowing in at least one direction. The technique involves ensonifying a thin sample volume of blood flow exiting the orifice, which volume is in a region of flow which is substantially laminar, with an ultrasonic pulsed Doppler signal; receiving backscattered signal from blood within the sample volume; forming a power-velocity spectrum from the received backscattered signal; and forming the power integral of the laminar flow from the spectrum, this power integral being proportional to an instantaneous cross-sectional area of the orifice. A time profile of instantaneous areas of flow for the orifice may be obtained by repetitively performing the laminar flow power integral measurement for successive time intervals. The portion of laminar flow in the power velocity spectrum is preferably determined. For preferred embodiments, the sample volume is at the vena contracta of flow exiting the orifice. The vena contracta is the smallest cross-sectional area traversed by flow just beyond the orifice, it being found that flow is substantially laminar at the vena contracta, this vena contracta being the region where entrainment of flow turbulence is at its minimum. For preferred embodiments, the ultrasonic Doppler signal is electronically steered and focused to the vena contracta and is preferably wide enough so as to fully ensonify the vena contracta. The electronic steering and focusing may be performed by moving the ultrasound signal through blood flow exiting the orifice, and detecting a Doppler spectral display and/or audio output, the signal being at the vena contracta when the Doppler signal consists primarily of laminar flow. To assure that only signal from laminar flow is utilized in performing the power integral calculation, the power velocity spectrum is preferably smoothed to eliminate the effects of any aberrations therein, and the velocity for peak power is determined for each time interval. A lower velocity of laminar flow is then determined as being a selected velocity, for example the maximum velocity, which is less than the velocity at peak power where the power is at a selected percentage of the peak power, and an upper velocity of laminar flow is determined which is a selected velocity, for example a minimum velocity, greater than the velocity at peak power where the power has dropped to a specified percentage of the peak power. Depending on application, the percentage of peak power may be from approximately 30% to approximately 60%, with approximately 50% or −3 db being the percentage of peak power for an illustrative embodiment. Only the power-velocity spectrum between the lower velocity and upper velocity, which is assumed to be derived from flow which is substantially laminar, is utilized in doing the power integral calculation, thus assuring that various values determined utilizing the teachings of this invention are obtained only from readings of laminar flow. The flow may for example be regurgitant flow through a faulty heart valve, the orifice area being that of lesions in the heart valve permitting the regurgitant flow. [0011]
  • The technique may also include calibrating to permit absolute flow area to be obtained. Calibrating may include applying a narrow ultrasound reference beam placed within the laminar flow in the vena contracta, the reference beam having a known cross-sectional area (CSA[0012] ref), and computing flow cross-sectional area (CSAflow) from CSAflow=CSAref·PImeas/PIref, where PImeas and PIref equal the power measure by a broad measurement beam encompassing the vena contracta and the power measure by the narrow reference beam of known cross-sectional area, respectively. Where the flow being measured is regurgitant flow through a faulty heart valve, calibration may be performed by detecting backscattered Doppler ultrasound power from the reference beam for forward flow when the valve is open.
  • The invention also involves a technique for obtaining instantaneous flow rates of blood passing through a dynamic orifice in at least one direction, which technique includes ensonifying a thin volume of blood flow exiting the orifice, which volume is in a region of flow which is substantially laminar, with an ultrasonic pulsed wave Doppler signal which fully encompasses the cross-sectional area of the volume where flow is substantially laminar; receiving backscattered signal from blood within the pulsed wave Doppler sample volume; forming a power-velocity spectrum from received backscattered signal; and forming the instantaneous power-velocity integral (PVI) from the laminar flow of the spectrum. A pulsed wave Doppler signal, such as high-PRF Doppler, capable of representing the full range of velocity, is preferred. A time profile of instantaneous flow rates for the orifice may be obtained by calculating the instantaneous power-velocity integrals for successive time intervals. As for the flow area determination, the thin sample volume is preferably at the vena contracta of the flow exiting the orifice, with electronic steering preferably being performed on the ultrasonic signal to steer and focus it to the vena contracta and is wide enough so as to fully ensonify the vena contracta. The electronic steering and focusing may be performed by scanning the ultrasound signal through blood flow exiting the orifice and detecting at least one of Doppler spectral display and audio output, the signal being at the vena contracta when the output of the detecting step identifies laminar flow. Flow at non-laminar velocities may be eliminated from the PVI determination in the manner described above. The flow may for example be regurgitant flow through a faulty heart valve, the orifice area being that of lesions in the heart valve permitting regurgitant flow. [0013]
  • Calibration may also be performed to permit absolute flow rate to be obtained, calibration including applying a narrow ultrasound reference beam placed within the laminar flow in the vena contracta, the reference beam having a known CSA (CSA[0014] ref), and computing Flow rate from Flow rate=CSAref·PVImeas/PIref. Where the flow being measured is regurgitant flow through a faulty heart valve, calibration may include detecting backscattered Doppler ultrasound power from the reference beam when the valve is open for forward flow.
  • Finally, the invention involves a technique for obtaining flow volume for blood passing through a dynamic orifice in at least one direction, which technique includes ensonifying a thin volume of blood flow exiting the orifice, which volume is in a region of flow which is substantially laminar, with an ultrasonic pulsed wave Doppler signal which fully encompasses the cross-sectional area of the volume where flow is substantially laminar; receiving backscattered signal from blood within the pulsed wave Doppler sample volume; forming a power-velocity spectrum from received backscattered signal; and forming the instantaneous power-velocity integral (PVI) from the laminar flow portion of the spectrum and the profile of the instantaneous flow rates. The flow volume is obtained from the time integral of the instantaneous flow rate (PVTI). As for prior embodiments, a pulsed wave Doppler signal, such as high-PRF Doppler, is preferred, the thin sample volume is preferably at the vena contracta of the flow exiting the orifice, the technique preferably includes electronic steering and focusing the ultrasonic signal to vena contracta, and non-laminar velocities being removed from the calculations using techniques previously discussed. The ultrasound signal is preferably wide enough so as to fully ensonify the vena contracta. The flow may for example be regurgitant flow through a faulty heart valve, the orifice area being that of lesions in the heart valve permitting regurgitant flow. Where the flow is regurgitant flow through a faulty heart valve, detected forward and regurgitant flow may be combined to obtain a measure of regurgitant fraction. [0015]
  • Calibration may also be performed to permit absolute flow volume to be obtained, calibration including applying a narrow ultrasound reference beam placed within the laminar flow in the vena contracta, the reference beam having a known CSA (CSA[0016] ref), and computing Flow volume from Flow volume=CSAref·PVTImeas/PIref. Where the flow being measured is regurgitant flow through a faulty heart valve, calibration may include detecting backscattered Doppler ultrasound power from the reference beam when the valve is open for forward flow.
  • The foregoing and other objects, features and advantages of the invention will be apparent from the following more particular description of preferred embodiments of the invention as illustrated in the accompanying drawings.[0017]
  • IN THE DRAWINGS
  • FIG. 1A is a representation of the anatomy and physiology of the human heart, FIG. 1B and FIG. 1C being enlarged views for a portion of the heart shown in FIG. 1A during diastolic and systolic phases, respectively; [0018]
  • FIG. 2A is an illustration of data acquisition using an ultrasonic transducer in accordance with the teachings of this invention; [0019]
  • FIG. 2B is an ultrasonic display for two-dimensional image mode, and FIG. 2C is an exemplary ultrasonic display at the vena contracta for Doppler mode; [0020]
  • FIG. 3 is a representation of the anatomy for a regurgitant jet; [0021]
  • FIG. 4A is a diagrammatic representation of the sonification of an area of flow by a Doppler beam for a Doppler angle θ=0; [0022]
  • FIG. 4B is a diagrammatic representation of an exemplary velocity distribution across an area of flow; [0023]
  • FIG. 4C is a plot of backscattered power versus frequency from the received Doppler spectrum shown in FIG. 4B [0024]
  • FIG. 4D is a plot illustrating the conversion of power and frequency to display video intensity and velocity; [0025]
  • FIGS. 4E and 4F are exemplary displays of actual flow measurements (velocity vs. time) by Doppler for in vitro steady flow and in vivo parabolic flow, respectively; [0026]
  • FIG. 5 is a diagrammatic illustration of the principle of volume flow rate calculation over an area of flow for a spectrum of three different flow velocities; [0027]
  • FIG. 6 is a diagrammatic representation illustrating the proportionality of backscattered Doppler power to a sonified volume of blood; [0028]
  • FIG. 7 is a diagram illustrating the independence of the power-velocity spectrum from the distribution of velocities across the flow CSA; [0029]
  • FIG. 8 is a diagrammatic representation illustrating calibration using a broad measurement beam and a narrow reference beam; [0030]
  • FIGS. [0031] 9A-9D are a high-PRF Doppler signal, an enlarged sector of the signal shown in FIG. 9A, a PI plot and a PVI plot, respectively for an exemplary orifice and flow profile;
  • FIG. 10 is a schematic representation of the flow phantom used for in vitro experiments for validation the teaching of this invention; [0032]
  • FIGS. 11A and 11B are plots of various results for PI achieved in an in vitro study of this invention; [0033]
  • FIG. 12 is a plot of various calculated and calibrated PVI values versus actual flow rates for in vitro experiments involving the teaching of this invention; [0034]
  • FIG. 13 is a plot of calculated and calibrated PVTI values versus actual regurgitant flow volumes for exemplary in vitro experiments involving the teaching of this invention; [0035]
  • FIG. 14 is a schematic diagram of an in vivo animal model used in performing in vivo experiments involving this invention; [0036]
  • FIG. 15 is a plot of calculated and calibrated mitral regurgitant stroke volume (MRSV) versus actual values of MRSV for in vivo animal experiments; [0037]
  • FIGS. [0038] 16A-16C are illustrative Doppler spectra for a patient with functional mitral regurgitation;
  • FIG. 17 is a plot of calculated and calibrated mitral regurgitant stroke volume (MRSV) versus independent reference values of MRSV in patient studies; [0039]
  • FIG. 18A is a schematic structure presentation, and FIG. 18B are plots useful in conjunction with Appendix A for describing the principles of pulse Doppler for blood velocity measurement; [0040]
  • FIG. 19 is a plot useful in conjunction with Appendix B for illustrating beam properties, and in particular the use of a smaller aperture to produce a larger beam CSA; and [0041]
  • FIG. 20 is a plot useful in conjunction with Appendix C for understanding broadening of the power-velocity spectrum of laminar flow.[0042]
  • DETAILED DESCRIPTION
  • Referring first to FIG. 1A, the heart is shown as having four chambers—left and right ventricle (LV and RV) and left and right atrium (LA and RA). These chambers are connected by four one-way valves, the mitral (MV), aortic (AV), tricuspid (TV) and pulmonary (PV) valves. There are also various vessels going in and out of the heart. The arrows in FIG. 1A indicate the direction of the blood where the venous return enters the right heart via the right atrium and is pumped by the right ventricle via pulmonary valve and pulmonary artery to the left and right lung. After oxygenation in the lungs, the blood re-enters the heart via the pulmonary veins and flows to the left ventricle via the left atrium and the mitral valve. The left ventricle, as the strongest contracting chamber, pumps the oxygenated blood to the entire body via the aortic valve and the aorta, thereby creating the systemic blood pressure. [0043]
  • FIGS. 1B and 1C indicate the direction of blood flow during the two phases of one heart cycle, diastole where the left ventricle relaxes to refill with blood from the left atrium, and systole where the left ventricle contracts to eject the blood to the aorta. FIG. 1C shows the pathologic regurgitant flow when the mitral valve closes incompletely during systole. [0044]
  • FIG. 2A illustrates the use of an ultrasonic transducer to acquire data on the heart. The ultrasonic transducer is positioned onto the outer chest wall of the patient, and its beam is oriented to the region of flow. A high-PRF Doppler sample volume is depicted, which is located in the vena contracta which, as indicated previously, is the narrowest portion of the jet. FIG. 2B shows how a two-dimensional image plane intersecting the heart is used to navigate the Doppler beam so as to place the sample volume at the vena contracta, which is at the white arrow in FIG. 2B. Once the beam is located, the system may be changed to pulsed Doppler mode to register the Doppler signal as depicted in FIG. 2C. The velocities are displayed below a baseline of 0, indicating that the flow is away from the transducer passing from the left ventricle through the diseased mitral valve back to the left atrium. [0045]
  • FIG. 3 is a diagram illustrating the anatomy of a regurgitant jet, illustrating the vena contracta, the core of laminar flow, and the regions of entrainment of fluid and turbulence. The vena contracta is shown as the narrowest portion of the regurgitant jet just below the orifice where velocities are highest and flow is larninar across the jet prior to entrainment of fluid and turbulence. The figure also indicates the Doppler beam and the sample volume located at the vena contracta. Cross-sectional views at the right indicate the laminar flow at the vena contracta and the turbulent flow beyond the vena contracta. [0046]
  • Basic Principles [0047]
  • Referring to FIG. 4A, for Doppler operation, the ultrasound system, through the use of a hand-held transducer, transmits an ultrasound beam that is electronically steered and focused. It is the backscattered ultrasound that provides the diagnostic information, the ultrasound energy within the beam backscattered as it propagates within the body. To acquire the backscattered signal, the ultrasound system operates in ‘reverse’ using the same transducer to receive the backscattered energy, again with electronic steering and focusing. [0048]
  • The spectral Doppler power is proportional to the volume of backscatterers on a frequency basis. This power spectrum is mapped to a vertical line of display intensity. The spectrum is computed and displayed continually and in real-time as depicted in FIGS. 4E and 4F. Parabolic flow (FIG. 4F) pertains to the shape of the narrow-band velocity trace over time from an in vivo pulsatile flow through a mitral valve regurgitant orifice during systolic left ventricular contraction in a patient. For FIG. 4C, power at f[0049] 2 is twice as large as at f1 or f3 because the area of V2 is twice as large as of V1 and V3.
  • In the Doppler modality of operation, the power spectrum of the demodulated received waveform is computed using an FFT algorithm and analyzed by the ultrasound imaging system. The analysis of the received Doppler signal provides two important components; the Doppler frequency and the corresponding backscattered signal strength (acoustic power). [0050]
  • The velocity of the backscattering medium, presumably blood within a sample volume at the focal region, is related to the frequency of the power spectrum of the backscattered ultrasound by the equation, [0051] f D = 2 f c V SC cos θ ( 1 )
    Figure US20030055336A1-20030320-M00001
  • where f[0052] D denotes the Doppler frequency of the backscattered signal, f denotes the transmit frequency of the ultrasound, c denotes the speed of propagation of sound within the medium, (the approximate speed of sound in water is 1470 m/sec, in soft tissue 1540 m/sec and in bone 4800 m/sec), VSC denotes the velocity of the scattering object, presumably blood, and θ denotes the angle between the direction of the ultrasound beam and the direction of blood velocity. A derivation of Eq. 1 based on the amplitude/phase data of the demodulated received signal rather than the basic Doppler concept is provided in Appendix A.
  • Using “somewhat conventional” procedures, for example the use of the fast Fourier transform (FFT), the spectral content of the backscattered Doppler signal is determined. The spectral bins of sufficient amplitude not only indicate blood flow at velocities as determined by Eq. 1, but also backscattered power is proportional to the amount of blood flowing at the corresponding velocity (FIG. 4C). However, in the present systems, where the Doppler spectrum of blood flow is generated and displayed in real-time, only the velocities are interpreted for diagnostic purposes. [0053]
  • The basic concept for using the Doppler spectral information to quantitate flow rate and volume is as follows: [0054]
  • First, referring to FIG. 5, for the purpose of concept presentation a lumen is defined, as a bounded cross-sectional planar area denoted by the vector A[0055] l→ of direction perpendicular to the planar surface, through which flows an incompressible fluid with directional velocity function v→(x, y, t) across the area of flow at instantaneous time t. The incremental flow δQ•(x, y, t) passing through the differential area δA→(x, y) at time t is given by v→(x, y, t)•δA→(x, y) where • denotes the dot product operation of two direction vectors. The dot product of two vectors a and b is defined as the product of their magnitudes times the cosine of the angle between them. The total flow passing through the planar cross-sectional area encompassed by the lumen is given by the integral expression Q · ( t ) = Ai v ( x , y , t ) · δ A ( x , y ) ( 2 )
    Figure US20030055336A1-20030320-M00002
  • The flow volume, Q[0056] v, within an interval of time, for example, within the systolic portion of the cardiac cycle, can be obtained by integrating the instantaneous flow over the time interval of interest denoted T, that is, Q v = T Q · v ( t ) t ( 3 )
    Figure US20030055336A1-20030320-M00003
  • The uniqueness of this approach is the capability to measure the regurgitant flow rate and flow volume noninvasively and directly at the valve lesion using only the backscattered power and velocity information, both of which are contained in the received ultrasound spectrum. This is accomplished as follows: A sample volume of cross-sectional area that encompasses the area of regurgitant flow at the vena contracta is sonified with the ultrasound beam. It is important to note that the flow within the sample volume when placed at the vena contracta contains the laminar flow of the vena contracta and nonlaminar flow of the blood surrounding the vena contracta unlike in prior art where blood flow was constrained within the wall of the vessel. While the Doppler spectrum from a sample volume applied to such a vessel only contains the signal from the vessel flow, the Doppler spectrum from the sample volume of a regurgitant jet at the level of the vena contracta contains signal from laminar and turbulent flow. This requires the identification of the laminar portion of the Doppler spectrum and the use only of this portion in the calculation of the measurements. [0057]
  • To accomplish the above, the operator of the system initially utilizes a standard ultrasonic beam control, such as a joy stick or tracker ball, to adjust the beam as shown in FIGS. 2A and 2B to pass through the mitral valve or other valve of interest. The depth for imaging is then adjusted on the machine in standard fashion so as to be directly adjacent a regurgitant side of the valve at the vena contracta. All this is done with the ultrasound system in image mode as shown in FIG. 2B, the desired imaging spot being generally at the bright dot being pointed to by the arrow. [0058]
  • At this point, the beam is focused at substantially the desired point, but may not be exactly centered with the flow to be measured. To fine tune the position, the ultrasound system is switched to Doppler mode, resulting in a display such as that shown in FIG. 2C, illustrating velocity versus time. FIG. 9A is an alternative image. The bright signals in the low velocity area on these displays, for example under 100, is generally tissue noise, turbulent flow, and the like, while the bright higher frequency band on the outside of each of these images is generally from laminar flow. When in the vena contracta where laminar flow predominates, the narrowness and cleanness of this bright narrow-band spectrum will be optimized. Generally, in order to eliminate the effect of aberrations in the backscattered signal, the backscattered signal is smoothed utilizing a standard averaging or smoothing technique. The operator then looks at the Doppler mode image and fine tunes transducer position and/or image depth until the “cleanest” observed image is obtained. Alternatively, the smoothed backscattered signal may be converted to audio, the signal from the vena contracta being the cleanest tone involving the fewest frequencies. Theoretically this fine tuning could be done automatically, with for example the beam position and depth being slightly adjusted through a small range, and for example an audio signal being monitored to provide a feedback signal for controlling the beam in a direction resulting in the cleanest audio output. This could be done first for position and then for depth, or the two could be done simultaneously in accordance with a selected feedback controlled scanning algorithm. [0059]
  • However, as indicated above, even when the beam is positioned exactly at the vena contracta, in order for the beam to ensonify the entire vena contracta, it will inherently also ensonify some of the surrounding turbulent flow. In order to ensure that only signal from laminar flow at the vena contracta is utilized for performing the various calculations in accordance with the teachings of this invention, a velocity filtering technique may be utilized, which technique is illustrated in FIGS. 9A and 9B. Referring to FIG. 9B, which is an enlarged image of the portion of FIG. 9A shown in the rectangle, it is seen that the backscattered signal contains a number of velocities, the power at a given velocity for the time t[0060] i being indicated by the brightness of the image for the velocity Vi at the given time, a brighter image indicating more power. For each time ti a determination is made of the velocity of peak power in the smoothed power-velocity spectrum for the sample ti in FIG. 9B, which is also shown at the right of the Figure. From this image, peak power is found to extend over a velocity range Vr, a velocity in this range being utilized as the velocity of peak power for this time interval. A determination is then made of the lower velocity of laminar flow (Vlow) which is considered to be the maximum velocity which is less than the velocity for peak power (i.e., VR) where the power is a specified percentage of peak power. This percentage may, for example, be in an approximate range of 30% to 60% of peak power depending on application, being 50% or −3 DB for an illustrative embodiment. Similarly Vhigh, the upper velocity of laminar flow is determined by finding the minimum velocity which is greater than the velocity VR of peak power where the power is the specified percentage of the peak power. While the specified percentage of peak power need not be the same for determining Vlow and Vhigh, these percentages are the same for an illustrative embodiment and would normally be the same. Once Vlow and Vhigh are determined for a given time tI, only backscattered radiation having a velocity falling within this range is utilized and performing the various calculations, thus assuring that only laminar flow at the vena contracta is being utilized for these calculations.
  • Pulse-wave (PW) Doppler is used since, as described in Appendix A, this allows a range gate to be set which in turn controls the thickness of the interrogated volume. In PW Doppler, a relatively short pulse is transmitted and the sample volume thickness is controlled by receiving and analyzing the backscattered ultrasound for a relatively short interval of time. The total backscattered acoustic power from such a Doppler sample volume is linearly proportional to the sonified blood volume, where the proportionality factor is given by the backscattering coefficient that is related to the number of independent scatterers, mainly red blood cells (erythrocytes), in this volume. [0061]
  • Further, if a disk-like sample volume is traversed by blood flow, then the backscattered power is linearly proportional to the cross-sectional area (CSA) of the flow within the lumen projected onto the surface of the sample volume of the sonifying ultrasound beam as shown in FIG. 6. This assumes that the thickness of the sample volume is thin and constant, that the concentration of scatterers (hematocrit) is constant, and that the beam encompasses the entire CSA of flow. For example, the total backscattered power from a jet with a CSA of 1.0 cm[0062] 2 would be twice as much as from a jet with a jet CSA of 0.5 cm2.
  • This approach does not require the existence of a lumen nor the explicit determination of the velocity distribution over the cross-sectional area of the vena contracta. Rather, the Doppler beam encompassing the entire area of flow, effectively integrates the contribution of all scatterers at each velocity of laminar flow regardless of the velocity profile (FIG. 7). That is, in the Doppler modality the backscattered acoustic signal power increases linearly by the number of scatterers traveling at the same velocity, independent of their individual locations within the jet CSA and independent of their individual locations within the sample volume. As a consequence, it becomes clear that with this application of the Doppler beam analyzing the backscattered power-velocity spectra, there are no longer concerns about the velocity distribution of scatterers across the flow CSA or about the shape and area of the flow CSA (FIG. 7), assuming a uniform sensitivity across the transmit and receive beam CSA. Thus, in FIG. 7, the areas of V[0063] 1, V2, and V3 in flows A and B having the same size but different shapes are represented by the same power spectrum.
  • In order to detect the weak backscattered signal from blood, the Doppler modality requires the elimination of signal backscattered from tissue prior to the calculation of the power spectrum, since the backscattered power of tissue can be 100 to 1000 times greater than the power backscattered by blood. This is done by a high-pass filtering process, referred to as a wall filter, that eliminates Doppler signals backscattered from low velocity targets such as tissue. Hence even though the backscattered power is independent of velocity, only the backscattered power of blood flow above the cutoff velocity of the wall filter is measured. From this it also becomes clear that blood within the sample volume that is not flowing, such as that external to the vena contracta, does not contribute to the power spectrum and therefore does not contribute to the area and associated flow measurement. [0064]
  • In summary, for a sample volume of uniform thickness, achieved with PW Doppler and placed in the vena contracta, the spectral Doppler power associated with a Doppler frequency, denoted P(v), is linearly proportional to the cross-sectional area of scatterers traveling at the velocity v, corresponding to the Doppler frequency. Hence, the total spectral power is linearly proportional to the cross-sectional area of the vena contracta. That is [0065] Power = vel P ( v ) v CSA jet ( 4 )
    Figure US20030055336A1-20030320-M00004
  • This is demonstrated in the results that are contained herein. [0066]
  • Furthermore, the power associated with a given frequency (or velocity) times the velocity is equivalent to the area times the velocity, which in turn provides a measure of the component of flow attributable to scatterers of the specified velocity. If this calculation of power times velocity is integrated for each component of the Doppler spectrum, an estimate proportional to the total instantaneous flow passing through the vena contracta, denoted Q•[0067] v(t), can be obtained. That is, Q · ( t ) vel P ( v ) v v ( 5 )
    Figure US20030055336A1-20030320-M00005
  • The flow volume can be obtained from the estimates of instantaneous flow by integrating over the time interval of interest denoted T. That is, [0068] Q v = T Q · ( t ) ( 6 )
    Figure US20030055336A1-20030320-M00006
  • These relationships are demonstrated in both in vitro and in vivo experiments to be discussed later. [0069]
  • From this discussion, it is seen that the Doppler power-velocity principle also indicates that the backscattered power integrated over the velocity spectrum at the vena contracta is proportional to the cross-sectional area of the vena contracta, regardless of flow rate. Of note is that the proportionality between power and CSA depends mainly on attenuation and the backscattering coefficient, which is a nonlinear function of hematocrit. The calibration technique described later, however, takes this into account by comparing measured power over the entire sample volume with that in a small reference beam of known CSA. [0070]
  • Finally, although there is a dependence of the velocity measurement on the angle θ between the direction of flow in the vena contracta and the main axis of the Doppler beam as indicated in Eq. 1, the measurement of power times velocity is independent of this angle. That is, the Doppler velocity is decreased by the cos θ and the power measurement, being proportional to the CSA of flow projected onto the surface of the sample volume, is increased by 1/cos θ, such that [0071] Flow rate = ( v · cos θ ) · ( Flow CSA cos θ ) ( 7 )
    Figure US20030055336A1-20030320-M00007
  • This angle independence becomes relevant in in vivo studies where the Doppler beam cannot always be aligned with the direction of flow. [0072]
  • In the following section, evidence is discussed establishing that the regurgitant flow volume can be estimated/quantified using only the power and velocity information acquired with Doppler ultrasound, the discussion including both methodology of the conducted experiments and the results. [0073]
  • Methodology [0074]
  • Procedures required in practicing the teaching of this invention included: 1) generation of a Doppler beam sufficiently wide to encompass the cross-sectional area of the vena contracta of a regurgitant jet, and 2) a method of calibration to compensate for variations in attenuation and the backscattering coefficient. The following is a brief description of each procedure: [0075]
  • Doppler Beam-Width [0076]
  • For an illustrative embodiment, the full 1.2 cm by 2.0 cm transducer aperture of the transducer used produces a beam having a cross-sectional area of approximately 3.1 mm in elevation by 5.2 mm in the lateral dimension at a 10 cm depth, based on defining the border of the beam CSA by where the sensitivity of the transducer drops to the half-maximal power or −3 db. To ensonify larger flow areas, a broader measurement was produced based on the principle that the smaller the transducer aperture, the broader the distal beam (see FIG. 8). The aperture for the left measurement beam was diminished with the application of a Tyvek (Dupont) mask over the transducer face. In vitro, a 7-mm diameter circular aperture was applied, thereby increasing the half-maximum-power beam-width at a 10-cm depth to approximately 6.75 mm (CSA=0.36 cm[0077] 2; Appendix B). However, it was necessary to use a 10-mm aperture creating a beam-width of 5.8 cm (CSA=0.26 cm2) at 10 cm for the in vivo experiments to minimize the loss of transmit power and Doppler receive sensitivity resulting from decreasing the size of the transducer aperture without compensating for the decrease of transmit power. Alternative beam broadening techniques are discussed in Appendix D.
  • Calibration of Doppler Power Measurements [0078]
  • Although the invention only requires that a proportionality exist between PVI and flow, it is necessary to calibrate the system in order to obtain absolute measurements of area and flow rate in a clinically useful manner. That is, in part because the power measurements obtained by the ultrasound system are unitless, and in part because for the same blood volume, Doppler power measurements will vary among patients due to differences in attenuation and backscattering coefficients (related to patient hematocrit). The Doppler measurements in each individual can be calibrated with a narrow reference beam that fits within an area of flow in the vicinity of the vena contracta (right beam FIG. 8). This beam is used to establish the ratio between reference power integral PI[0079] ref and the known CSA of the reference beam at that depth, CSAref. The same ratio can be applied to the power measured by the broader measurement beam, PImeas, in order to determine the CSA of flow within the beam, provided the measurement beam encompasses the entire cross-sectional area of the vena contracta. That is PI meas Flow CSA = PI ref CSA ref ( 8 )
    Figure US20030055336A1-20030320-M00008
  • For example, if the power is four times as great as that returning from the reference signal (the narrow beam obtained with the full transducer aperture), the flow CSA at the vena contracta is four times the known CSA of the reference beam. Since the area of the reference beam is known, the calibrated power measurement provides an estimate of the flow CSA at the vena contracta. [0080]
  • For the illustrative embodiment, the technique used to widen the beam also reduced the transmit power and receive sensitivity due to the reduced aperture size. That is, the power measured by the broader beam is less than that of the reference beam for the same cross-sectional area of flow, assuming the cross-sectional area of flow is contained within both the narrow reference and broader measurement beam (Appendix B). Hence, there is also the need to correct for the reduction in transmit power and receive sensitivity simply resulting from the reduction in the aperture of the transducer. The relationship of the ratios of power to cross-sectional area for this condition is, [0081] CF · PI ref Flow CSA = PI ref CSA ref ( 9 )
    Figure US20030055336A1-20030320-M00009
  • where CF denotes the correction factor accounting for aperture reduction. This correction factor was determined in vitro by comparing the backscattered power for both beams for flow through an orifice smaller in cross-sectional area than both beam-widths (0.07 cm[0082] 2; Appendix B). In this case, as the transducer aperture was reduced to 11 mm in diameter, the Doppler power measurement decreased by a factor of 5.0, so that the power measurement must be multiplied by a correction factor of 5.0 before it can be compared with the power of the reference beam to determine the cross-sectional area of the jet at the vena contract.
  • In order to determine the ratio between power and area, the backscattered power from the narrow reference beam alternatively can be captured in the filling phase of the mitral valve when the valve is wide open (FIG. 1B); that is because the ratio only requires backscattered power from the flow region of interest independent from velocity. This potentially would ease the application of the PVI approach because placing the reference beam into a small lesion can be difficult. Generally, this indicates that the power measurement with the reference beam in laminar flow can be performed independent of velocity and direction of flow. [0083]
  • The calibration procedure may be simplified by having the two required beams, the narrow reference and the broad measurement beam, generated simultaneously. This is done by taking advantage of a modern digital ultrasound system's capability, the basic principle being as follows: On transmit, the transducer generates a broad and relatively uniform beam that sonifies the entire area of flow as discussed in Appendix D. On receive, the two required beams, the narrow reference and the broad measurement beam, are generated simultaneously by the connection of the transducer elements to two independent digital beam-forming processors. Thus, the Doppler signal information can be acquired and calibrated in a single cardiac phase, thereby eliminating the need to perform a separate calibration operation. [0084]
  • If a measurement of absolute flow is not required, calibration is not necessary. For example, the regurgitant fraction, which is the ratio of regurgitant flow volume to forward flow volume through the valve, can be measured using this non-invasive approach. Measurements are obtained of the regurgitant flow volume and the forward flow volume associated with the valve. Since the measurement of regurgitant fraction consists of the ratio of the two measurements, calibration is not necessary. [0085]
  • System Settings [0086]
  • In all experimental results to now be described, a 2.5 MHZ linear array transducer of 96 elements operating at a Doppler frequency of 1.8 MHZ connected to a Hewlett-Packard 5500 phased array sector scanner was used. The highest-velocity and narrowest-spectrum velocity profile just beyond the regurgitant orifice, from laminar flow at the vena contract, was recorded with high pulse repetition frequency (high-PRF) Doppler mode with a maximum velocity scale of up to 800 cm/s (for details about high-PRF Doppler see Appendix A). A relatively thin sample volume of axial gate length of 0.35 cm was used and, to prevent signal suppression at low flow rates, a low velocity filter (wall filter) cut-off of 200 Hz (˜8 cm/s) was selected. Settings of compress and reject, transmit power, receive gain, depth, and velocity range were kept constant in the entire in vitro series as well as within each patient and animal to allow comparison of returned signals during each series. [0087]
  • Data Recording and Analysis [0088]
  • Doppler spectra were stored digitally, converted off-line to ASCII format and analyzed with MATLAB software (Version 5.1, MathWorks, Natick, Mass.). Power and power times velocity were then integrated over all velocities in the velocity spectrum corresponding to laminar flow in the vena contracta (FIG. 9). In steady flow, PI (power integral) and PVI (power-velocity integral) were computed over each vertical line of the spectral Doppler display (corresponding to a 128-point FFT) and averaging as many as 300 lines in the uncompressed image matrix of power values. For the experiments, each vertical image line represented a time interval of 4.9 ms. In pulsatile flow, the PVI was integrated over time to obtain PVTI (power-velocity time integral) as a measure of regurgitant blood flow volume within one cardiac phase. The difference between PI and PVI is seen in FIG. 9: PI is relatively constant during flow, given the constant in vitro orifice area, whereas PVI, reflecting the flow rate, varies over time and mirrors the velocity as expected for a fixed orifice. [0089]
  • Results [0090]
  • In vitro and in vivo test results for the Doppler power-velocity based technique described above, preceded by a brief explanation of the experimental setup, are presented in the following sections. [0091]
  • In Vitro Setup [0092]
  • For in vitro validation of the Doppler power-velocity concept for quantification of flow area, flow rate and flow volume for a dynamic orifice, a flow phantom was built to simulate the condition of regurgitant flow at the mitral valve. The flow phantom (FIG. 10) consisted of a variable diameter orifice located 10 cm from the ultrasound transducer acoustic window (typical distance in vivo of a mitral regurgitant orifice from the transducer placed on the chest surface; see FIG. 2A), with flow passing from a large cylindrical chamber (5.7 cm diameter; mimicking the LV) to an unconfined receiving chamber (mimicking the LA). Circular orifice areas of 0.2, 0.5 and 0.8 cm[0093] 2 were studied at 5 steady flow rates from 20 to 60 ml/s produced by a piston pump (modified Mark IV Powerinjector, Medrad, Inc., Indianola, Pa.) that minimized cavitation, as opposed to impeller-based pumps which were found to produce microairbubbles by cavitation, and with 6 parabolic pulses of regurgitant stroke volumes of 20 to 70 ml (4 different-shaped flow profiles for each stroke volume) produced by syringe injections. Initial studies with outdated blood or blood analogs containing surfactant produced microairbubbles due to cavitation as fluid encountered the pressure drop at the orifice. These microairbubbles severely contaminated the power measurements due to their strong backscattering properties. This was resolved using degassed distilled water with 19% glycerol (resulting specific gravity=1.043 gm/cm3) with a backscattering coefficient equivalent to that of whole human blood, produced by adding 48,600 polystyrene microspheres/ml (25.2 micron diameter; catalog no. DC-25; Duke Scientific Corp., Palo Alto, Calif.).
  • This flow phantom consisting of two chambers separated by an orifice models the similar condition of valvular stenosis and trans-septal shunting, and hence the results are equally applicable to the application of this procedure to quantification of stenotic valve opening area and shunt area and flow. [0094]
  • In Vitro Results [0095]
  • For all orifice sizes and flow rates, a clear narrow bright band of intensities at the highest velocities corresponding to the laminar flow at the vena contracta was detected in both steady and pulsatile flow. FIG. 12A shows that, as proposed, there was a linear proportionality between the power integral and the regurgitant orifice area (ROA) up to and including 0.5 cm[0096] 2 in area (r=0.99); an extreme orifice area of 0.8 cm2 was incompletely measured with the beam size used in the experiments (PI below the regression line for the other orifices). This, however, illustrates the importance of having a measurement beam that is broad enough to fully ensonify the area of the vena contracta.
  • These power values were measured using the expanded beam created by reducing transducer aperture to a diameter of 7 mm. Calibration was achieved with the narrow reference beam produced by the fill aperture. FIG. 12B demonstrates that this narrow beam fit within all the orifices used and therefore returned the same power regardless of orifice area and flow rate over the 32 combinations studied. This narrow beam was then used to create the following calibrations:[0097]
  • ROA=c cal•measurement beam PI
  • Q=c cal•measurement beam PVI
  • RSV=c cal•measurement beam PVTI
  • where c[0098] cal=(reference beam CSA/reference beam PI) times the correction factor (CF) needed to account for the decrease in power related to aperture reduction (see Eq. 9). The correction factor CF and the reference beam CSA are determined in vitro; only reference and measurement beam PI need to be measured in vivo. In vitro, reference beam CSA was 0.125 cm2 and CF was 63 (Appendix B, 7 mm aperture). With calibration, PI values were converted to regurgitant orifice area (ROA) and correlated and agreed well to actual ROA less than 0.8 cm2 (FIG. 12A, right-hand axis, y=0.84x+0.01 cm2, SEE=0.01 cm2), with slight underestimation of the anatomic orifice areas of 0.2 and 0.5 cm2 since the cross-sectional area of the vena contracta is known to be slightly smaller as determined by a contraction coefficient.
  • For the 0.07, 0.2 and 0.5 cm[0099] 2 orifices, flow rates calculated from PVI correlated linearly with actual flow rates (FIG. 13; r=0.99, y=0.95x+0.21 ml/s, SEE=2.5 ml/s). Similar correlation (FIG. 14; r=0.99, y=0.92x+1.3 ml, SEE=2.6 ml) was observed for the 72 studied pulsatile flow volumes calculated from PVTI.
  • With increasing velocity, a broader velocity spectrum was observed, raising the possibility of turbulent flow. However, as shown in Appendix C, the spectral bandwidth, measured as the central range of velocities in which 95% of scatterers travel (95% of power), was always roughly 20% of the power-weighted mean velocity (PWMV), indicating effectively laminar flow. [0100]
  • In Vivo Experiments [0101]
  • In vivo results are based both on animal experiments and on human patient studies. The animal experiments are presented first. The patient results, including data derived from three-dimensional (3D) ultrasound and magnetic resonance imaging (MRI) techniques for independent reference follow. [0102]
  • Animal Study Setup [0103]
  • In order to retain the native leaflets of the mitral valve, most comparable to the physiologic situation, and to measure MR volume directly, we developed the new canine model (FIG. 15). A nondistensible left atrial chamber was sutured to the native mitral annulus via a Dacron sewing ring, and the atrial walls sutured tightly around it to prevent leaking. This chamber was attached via nondistensible tubing to a vertical 1.0 cm diameter column. In the presence of a rigid left atrium, the entire MR stroke volume (MRSV) produced a vertical fluid excursion in the attached column with each systole (1.3 cm=1 ml), this excursion was videotaped and measured. Using this system, a total of 36 different hemodynamic stages were analyzed in 3 dogs, in each of which a regurgitant orifice of different size (0.12 to 0.21 cm[0104] 2) was cut into the anterior mitral valve leaflet and afterload changed by clamping the aorta to vary the amount of regurgitant flow.
  • All procedures were approved by the institutional Animal Care Committee based on NIH (National Institute of Health) principles. [0105]
  • Animal Study Results [0106]
  • During each hemodynamic stage, regurgitant stroke volume as measured based on the video camera recordings was stable over the time of recording (10-20 cycle). FIG. 16 shows results for MRSV calculated from the power measurements versus directly measured values of MRSV (left atrial column excursions) for 36 hemodynamic stages in all three animals. Actual values of mitral regurgitation stroke volume ranged from 4 to 21 ml. Calculated and actual values correlated excellent (y=0.98x+0.28 ml, r=0.98, SEE=0.89 ml). [0107]
  • Patient Study Setup [0108]
  • To demonstrate that the Doppler power principle can in fact be applied in patients, the amount of mitral regurgitant flow volume (MRSV) that occurs in each systolic phase of the heart cycle was determined in eleven patients (age 65±13 years; 8 male, 3 female) with at least mild to moderate mitral regurgitation of different etiologies, using the same methods applied in vitro. In all patients, values for MRSV by Doppler power were compared with those calculated from left ventricular ejection volume by three-dimensional echocardiography minus forward aortic stroke volume derived from left ventricular outflow tract CSA times the time integral of the power-weighted mean velocity measured in the LV outflow tract, which takes into account the velocity spectrum within the beam. PVI measurements were also compared with estimates of mitral regurgitant stroke volume obtained using MRI in three patients. To date the MRI approach represents the most trusted procedure for quantification of regurgitant flow. However, it is extremely time consuming, requiring patient confinement within the bore of the magnet of 1 hour, and is prohibitively expensive and not practical for this application. [0109]
  • Patient Study Results [0110]
  • In all patients, a satisfactory high-PRF Doppler signal with a narrow velocity spectrum from laminar flow at the vena contracta was obtained; including those with eccentrically directed jets. FIG. 17 shows an example of such a velocity spectrum in a patient with functional mitral regurgitation. Of note is that the power integral has early and late systolic peaks and mid-systolic decrease, which is the recognized pattern for regurgitant orifice area in such patients since the two valve leaflets are pushed together in mid-systole by the peak LV pressure, which decreases the orifice area. [0111]
  • Values of mitral regurgitant stroke volume in the eleven patients as measured by the reference techniques ranged from 8.0 to 50.1 ml representing mild to severe regurgitation. Correlation between the PVTI estimates of MRSV and reference values are shown in FIG. 18 (r=0.99, y=0.72x+3.4 ml, SEE=1.45 ml). The correlation is good for flow volumes up to 20 ml. However, there is underestimation of regurgitant volumes above 20 ml that is attributed to the limited measurement beam size used in these experiments; that is, the larger regurgitant flow volumes correspond to large regurgitant orifices which exceeded the cross-sectional area of the measurement beam. It is anticipated that with a broader measurement beam this underestimation of the higher regurgitant stroke volumes can be eliminated. [0112]
  • Conclusions [0113]
  • Ultrasound over the past twenty years has proven to be extremely valuable as a noninvasive medical diagnostic tool not only for cardio-vascular diseases but also for prenatal and gynecologic examinations, and for diseases of the liver and kidneys among others. Some new uses include tissue characterization, breast cancer identification, and eye examinations. However, though the target of many researchers worldwide, the direct and noninvasive quantification of regurgitant pathologic volume flow in the human heart is still not possible. Existing ultrasound approaches, either based on simplification of the regurgitant pathologic flow model or on complex multi-step procedures, do not measure the flow directly at the lesion of the valve and have failed to provide satisfactory results. For example, direct measurement of the regurgitant flow, is dependent upon the knowledge of the area of flow, which is difficult to measure due to its complex and dynamically changing geometry; until the development of this invention no ultrasound technique has been available to provide such a measurement in a reliable and useful manner. [0114]
  • The innovative approach of this invention is based on the integral of backscattered acoustic power, which, in principle, provides a measure of flow cross-sectional area. Although the basic physics of flow and ultrasound indicate the integral of Doppler power times velocity can measure flow rate and flow volume, investigators have felt this principle could not be applied to regurgitant pathologic jets comprised of high-velocity flow in the human heart because backscattered power is variably increased by turbulence and entrainment of fluid. For that reason previous studies using Doppler power evaluated only flows that were restricted to a conduit (tube, large vessel, or ventricular outflow tract) and therefore considered laminar. This invention demonstrates that this limitation can be overcome by integrating power times velocity in the narrow velocity spectrum obtained from flow passing through a thin sample volume placed in the vena contracta, that is, at the origin of the regurgitant jet, where flow is mostly laminar since turbulence has not yet developed. [0115]
  • The approach of this invention has several advantages. First, regurgitant flow rate and volume can be measured using only the backscattered power and velocity information as obtained by ultrasound Doppler. Because, integrating backscattered power times velocity over the Doppler spectrum automatically contains a measure of the flow cross-sectional area due to the proportionality of backscattered power to flow area, this approach overcomes the limitations of most techniques that require a separate area measurement. Second, the thin Doppler sample volume can be placed directly at the lesion where regurgitant flow occurs, making possible the most direct and therefore accurate measurement of regurgitant flow area and flow volume. Third, with this approach there are no simplifying assumptions about the velocity distribution across the flow area, because the Doppler beam effectively integrates all incremental areas of different flow rates. There are also no concerns about the spectrum of velocities because the approach integrates backscattered power times velocity over the entire velocity spectrum, as long as the spectrum is reasonably narrow indicating mostly laminar flow. Finally, the power-velocity measurement, is independent from variations in the angle θ between the direction of flow and the main axis of the Doppler beam. It has been shown that this principle is correct at least for angles from 0 to 45°. [0116]
  • It is important to realize that the size and shape of a regurgitant orifice in vivo is varying throughout the period of regurgitation, thereby limiting the ability of existing techniques which rely upon a single estimate of the orifice area, since no satisfactory procedures were available to record these dynamic changes. The beauty of the PVI approach is that, because the Doppler beam effectively integrates all incremental areas of different flow rates independent of their local distribution across the beam area, there are no longer concerns about the complex shape and size of the dynamic flow cross-sectional area or the regurgitant orifice. This is also important because different shapes and sizes of regurgitant orifices caused different complex flow fields around the valve lesion thereby limiting the accuracy of other techniques based on rather simplistic geometric flow field assumptions. [0117]
  • This concept was applied in an ideal in vitro environment, in a more realistic experimental in vivo setting with a direct goldstandard, as well as in patients, with very good results, demonstrating a linear proportionality between flow cross-sectional area and the Doppler power integral (PI), between regurgitant flow rate and the integral of Doppler power times velocity (PVI), and between regurgitant stroke volume and the time integral of the integral of Doppler power times velocity (PVTI), all measured directly at the vena contracta. These results, and the narrow velocity spectra observed even for relatively small orifices and eccentric jets in patients, suggest that no significant turbulence develops at the vena contracta that would interfere with this proportionality. Besides demonstrating the proof of the PVI concept, the practicability and accuracy of this new approach was successfully demonstrated in patients with various mitral valve diseases leading to mitral regurgitation. [0118]
  • Future systems may be developed which simplify the procedure for routine clinical application. The described system has an ultrasound transducer capable of creating a broad and uniform measurement beam and a narrow reference beam for calibration purposes. Thereafter a manual, partially automated or fully automated analysis of the Doppler signal is performed by the system, identifying the narrow Doppler spectrum associated with laminar flow in the vena contracta and calculating PI, PVI, and PVTI. Finally, the results of the measurement beam are calibrated taking into account transmit power, receive gain, and other relevant system settings, thereby producing and displaying measurements of diagnostic importance such as peak cross-sectional area of flow, mean cross-sectional area of flow, peak flow rate, mean flow rate, stroke volume and regurgitant fraction. [0119]
  • Beyond the presented application in mitral valve regurgitation, this new concept can be applied to other diseases associated with flow through dynamic orifices; for example regurgitant flow of each of the four heart valves, as well as valvular stenosis, septal defects with shunt flow, and peripheral vascular disease with vessel obstruction, where valvular stenosis refers to restricted forward flow due to a condition that prevents the valve from opening completely and a septal defect refers to a pathologic orifice in the septum that separates the right and the left side of the heart. In particular, accurate noninvasive measurement of stenotic (restricted) valve opening areas based on the calibrated power integral would critically improve diagnosis and treatment of stenotic valve disease. Ultimately, this PVI approach could be used to obtain regurgitant fraction as the ratio of regurgitant flow volume to normal forward flow volume; this would require a beam encompassing the cross-sectional area of forward flow when the valve is open. The beauty of this approach would be that both regurgitant and forward volume could be determined from the same sample volume. By adding regurgitant and forward flow volume at the mitral valve, cardiac output, one of the most important clinical parameters, is obtained, where cardiac output refers to the volume of blood pumped by the heart in a cardiac cycle. [0120]
  • Thus, the PVI concept can overcome the limitations of existing techniques that are invasive, costly, and inaccurate and has the potential to replace them. [0121]
    Figure US20030055336A1-20030320-P00001
    Figure US20030055336A1-20030320-P00002
    Figure US20030055336A1-20030320-P00003
    Figure US20030055336A1-20030320-P00004
    Figure US20030055336A1-20030320-P00005
    Figure US20030055336A1-20030320-P00006

Claims (89)

1. A method for obtaining an area for a dynamic orifice through which blood is flowing in at least one direction comprising:
a) ensonifying a sample volume of blood flow exiting the orifice, which volume is in a region of said flow which is substantially laminar, with an ultrasonic pulsed Doppler signal;
b) receiving backscattered signal from blood within said sample volume;
c) forming a power-velocity spectrum from received backscattered signal; and
d) forming an instantaneous power integral of laminar flow for the power-velocity spectrum, said power integral being proportional to instantaneous cross-sectional area of the orifice.
2. A method as claimed in claim 1 including (e) determining the portions of laminar flow in said power velocity spectrum.
3. A method as claimed in claim 2, wherein step (e) includes (e′) identifying a narrow velocity spectrum of laminar flow to be used in forming the power integral, said step (e′) including:
(i) smoothing the power-velocity spectrum;
(ii) determining the velocity of peak power in a smoothed power-velocity spectrum;
(iii) determining a lower velocity of laminar flow, said lower velocity being a selected velocity less than the velocity for peak power where the power is a specified percentage of the peak power; and
(iv) determining an upper velocity of laminar flow, said upper velocity being a selected velocity greater than the velocity of peak power where the power is a specified percentage of the peak power.
4. A method as claimed in claim 1, wherein said sample volume is at the vena contracta of flow exiting the orifice.
5. A method as claimed in claim 4, including the step (f) of steering and focusing the ultrasonic signal to said vena contracta.
6. A method as claimed in claim 5, wherein step (f) includes utilizing an image mode display of backscattered signal to steer and focus the signal to the vena contracta, and utilizing at least one of a Doppler mode power/time display and audio signal to fine tune steering/focusing of the ultrasonic signal to the vena contracta.
7. A method as claimed in claim 1, wherein said ultrasonic signal to be used for said power integral measurement (PImeas) is wide enough to fully ensonify the cross-sectional area of the laminar flow.
8. A method as claimed in claim 1, including repeating steps a), b), c) and d) to obtain a profile of flow area over time.
9. A method as claimed in claim 1, wherein said flow is regurgitant flow though a faulty heart valve, the orifice area being that of lesions in the heart valve permitting the regurgitant flow.
10. A method as claimed in claim 1, wherein said flow is stenotic flow through a restricted heart valve, the orifice area measurement being the restricted valve opening area permitting the flow in normal direction through the valve.
11. A method as claimed in claim 1, wherein said flow is shunt flow through a shunt lesion, the orifice area measurement being of shunt lesions permitting the shunt flow.
12. A method as claimed in claim 1, wherein said flow is stenotic flow through a restricted peripheral vessel, the orifice area measurement being the restricted area of flow.
13. A method as claimed in claim 1, including the step of (g) of calibrating to permit absolute area of laminar flow to be obtained.
14. A method as claimed in claim 13, wherein step (g) includes applying a narrow ultrasound reference beam within said region, said reference beam having a known CSA (CSAref), and computing Flow CSA from Flow CSA=CSAref·PImeas/PIref.
15. A method as claimed in claim 14, wherein said flow is regurgitant flow through a faulty heart valve, and wherein step (g) includes detecting Doppler ultrasound power from said reference beam when the valve is open for forward flow.
16. A method for obtaining flow rate of blood passing through a dynamic orifice in at least one direction comprising:
a) ensonifying a sample volume of blood flow exiting the orifice, which volume is in a region of said flow which is substantially laminar, with an ultrasonic pulsed Doppler signal;
b) receiving backscattered signal from blood within said sample volume;
c) forming a power-velocity spectrum from received backscattered signal; and
d) forming an instantaneous power-velocity integral of laminar flow for the power-velocity spectrum as the integral of power times velocity, said power-velocity integral being proportional to instantaneous flow rate of the laminar flow.
17. A method as claimed in claim 16, including (e) identifying a narrow velocity spectrum of laminar flow to be used in forming the power-velocity integral, said step (e) including:
(i) smoothing the power-velocity spectrum;
(ii) determining the velocity of peak power in a smoothed power-velocity spectrum;
(iii) determining a lower velocity of laminar flow, said lower velocity being a selected velocity less than the velocity for peak power where the power is a specified percentage of the peak power; and
(iv) determining an upper velocity of laminar flow, said upper velocity being a selected velocity greater than the velocity of peak power where the power is a specified percentage of the peak power.
18. A method as claimed in claim 16, wherein said sample volume is at the vena contracta of flow exiting the orifice.
19. A method as claimed in claim 18, including the step (f) of steering and focusing the ultrasonic signal to said vena contracta.
20. A method as claimed in claim 19, wherein step (f) includes utilizing an image mode display of backscattered signal to steer and focus the signal to the vena contracta, and utilizing at least one of a Doppler mode power/time display and audio signal to fine tune steering/focusing of the ultrasonic signal to the vena contracta.
21. A method as claimed in claim 16, wherein said ultrasonic signal to be used for said power-velocity integral measurement (PVImeas) is wide enough to fully ensonify the cross-sectional area of the laminar flow.
22. A method as claimed in claim 16, including repeating steps a), b), c) and d) to obtain a profile of instantaneous flow rates over time.
23. A method as claimed in claim 16, wherein said flow is regurgitant flow though a faulty heart valve, the flow rate being that passing through lesion in the heart valve permitting the regurgitant flow.
24. A method as claimed in claim 16, wherein said flow is stenotic flow through a restricted heart valve, the flow rate being that passing through the restricted valve opening area permitting the flow in normal direction through the valve.
25. A method as claimed in claim 16, wherein said flow is shunt flow through a shunt lesion, the flow rate being that passing through shunt lesions permitting the shunt flow.
26. A method as claimed in claim 16, wherein said flow is stenotic flow through a restricted peripheral vessel, the flow rate being that passing through the restricted area of flow.
27. A method as claimed in claim 16, including the step of (g) of calibrating to permit absolute flow rate to be obtained.
28. A method as claimed in claim 26, wherein step (g) includes applying a narrow ultrasound reference beam within said region, said reference beam having a known CSA (CSAref), and computing Flow rate from Flow rate=CSAref·PVImeas/PIref.
29. A method as claimed in claim 28, wherein said flow is regurgitant flow through a faulty heart valve, and wherein step (g) includes detecting Doppler ultrasound power from said reference beam when the valve is open for forward flow.
30. A method as claimed in claim 16, wherein said pulsed wave Doppler signal is a high-PRF Doppler signal.
31. A method for obtaining flow volume of blood passing through a dynamic orifice in at least one direction comprising:
a) ensonifying a sample volume of blood flow exiting the orifice, which volume is in a region of said flow which is substantially laminar, with an ultrasonic pulsed Doppler signal;
b) receiving backscattered signal from blood within said sample volume;
c) forming a power-velocity spectrum from received backscattered signal;
d) forming the instantaneous integral of power times velocity for laminar flow of the power-velocity spectrum;
e) repeating step (d) to produce a time profile of the instantaneous flow rate; and
f) forming the time integral of the instantaneous flow rate profile for an interval of time where flow volume is to be measured, said time integral of instantaneous power-velocity integral being proportional to flow volume.
32. A method as claimed in claim 31, including (e) identifying a narrow velocity spectrum of laminar flow to be used in forming the power-velocity integral, said step (e) including:
(i) smoothing the power-velocity spectrum;
(ii) determining the velocity of peak power in a smoothed power-velocity spectrum;
(iii) determining a lower velocity of laminar flow, said lower velocity being a selected velocity less than the velocity for peak power where the power is a specified percentage of the peak power; and
(iv) determining an upper velocity of laminar flow, said upper velocity being a selected velocity greater than the velocity of peak power where the power is a specified percentage of the peak power.
33. A method as claimed in claim 31, wherein said sample volume is at the vena contracta of flow exiting the orifice.
34. A method as claimed in claim 33, including the step (f) of steering and focusing the ultrasonic signal to said vena contracta.
35. A method as claimed in claim 34, wherein step (f) includes utilizing an image mode display of backscattered signal to steer and focus the signal to the vena contracta, and utilizing at least one of a Doppler mode power/time display and audio signal to fine tune steering/focusing of the ultrasonic signal to the vena contracta.
36. A method as claimed in claim 31, wherein said ultrasonic signal to be used for said power-velocity time integral measurement (PVTImeas) is wide enough to fully ensonify the cross-sectional area of the laminar flow.
37. A method as claimed in claim 31, wherein said flow is regurgitant flow though a faulty heart valve, the flow rate being that passing through lesion in the heart valve permitting the regurgitant flow.
38. A method as claimed in claim 31, wherein said flow is stenotic flow through a restricted heart valve, the flow volume being that passing through the restricted valve opening area permitting the flow in normal direction through the valve.
39. A method as claimed in claim 31, wherein said flow is shunt flow through a shunt lesion, the flow volume being that passing through shunt lesions permitting the shunt flow.
40. A method as claimed in claim 31, wherein said flow is stenotic flow through a restricted peripheral vessel, the flow volume being that passing through the restricted area of flow.
41. A method as claimed in claim 31, including the step (h) of calibrating to permit absolute flow volume to be obtained.
42. A method as claimed in claim 41, wherein step (h) includes applying a narrow ultrasound reference beam within said vena contracta, said reference beam having a known CSA (CSAref), and computing Flow volume from Flow volume=CSAref·PVTImeas/PIref.
43. A method as claimed in claim 42, wherein said flow is regurgitant flow through a faulty heart valve, and wherein step (h) includes detecting Doppler ultrasound power from said reference beam when the valve is open for forward flow.
44. A method as claimed in claim 43, including the step of determining cardiac output, said step including:
(i) measuring blood flow volume passing through a heart valve orifice in the forward direction;
(ii) measuring regurgitant blood flow volume passing through the valve orifice in the reverse direction; and
(iii) summing the measurements of (i) and (ii) so as to provide a measure of the cardiac output.
45. A method as claimed in claim 43, including the step of computing the fraction of reverse versus forward flow, said step including:
(i) the uncalibrated measuring of blood flow volume passing through the orifice in the forward direction;
(ii) the uncalibrated measuring of regurgitant blood flow volume passing through the orifice in the reverse direction; and
(iii) combining the measurements of (i) and (ii) so as to provide a measure of the regurgitant fraction.
46. A method as claimed in claim 31, wherein said pulsed wave Doppler signal is a high-PRF Doppler signal.
47. Apparatus for obtaining an area of a dynamic orifice through which blood is flowing in at least one direction including:
(a) means for ensonifying a sample volume of blood flow exiting the orifice, which volume is in a region of said flow which is substantially laminar, with an ultrasonic pulsed Doppler signal;
(b) a receiver for backscattered signal from blood within said sample volume;
(c) means for forming a power-velocity spectrum from received backscattered signal; and
(d) means for forming the instantaneous power integral for laminar flow of the power-velocity spectrum, said power integral being proportional to instantaneous cross-sectional area of the orifice.
48. Apparatus as claimed in claim 47, including means for determining the portions of laminar flow in said power velocity spectrum.
49. Apparatus as claimed in claim 48, including means for identifying a narrow velocity spectrum of laminar flow to be used in the power integral calculation, said means including:
(a) means for smoothing the power-velocity spectrum;
(b) means for determining the velocity of peak power in a smoothed power-velocity spectrum;
(c) means for determining a lower velocity of laminar flow, said lower velocity being a selected velocity less than the velocity for peak power where the power is a specified percentage of the peak power; and
(d) means for determining an upper velocity of laminar flow, said upper velocity being a selected velocity greater than the velocity of peak power where the power is a specified percentage of the peak power.
50. Apparatus as claimed in claim 47, wherein said sample volume is at the vena contracta of flow exiting the orifice.
51. Apparatus as claimed in claim 47, including means for steering and focusing the ultrasonic signal to said vena contracta.
52. Apparatus as claimed in claim 47, wherein said ultrasonic signal to be used for said power integral measurement (PImeas) is wide enough to fully ensonify the cross-sectional area of the laminar flow.
53. Apparatus as claimed in claim 47, including means for obtaining a profile of flow area over time by successively operating means a), b), c), and d).
54. Apparatus as claimed in claim 47, wherein said flow is regurgitant flow though a faulty heart valve, the orifice area being that of lesions in the heart valve permitting the regurgitant flow.
55. Apparatus as claimed in claim 47, wherein said flow is stenotic flow through a restricted heart valve, the orifice area measurement being of the restricted valve opening area permitting the flow in normal direction through the valve.
56. Apparatus as claimed in claim 47, wherein said flow is shunt flow through a shunt lesion, the orifice area measurement being of shunt lesions permitting the shunt flow.
57. Apparatus as claimed in claim 47, wherein said flow is stenotic flow through a restricted peripheral vessel, the orifice area measurement being the restricted area of flow.
58. Apparatus as claimed in claim 47, including means for calibrating to permit absolute area of laminar flow to be obtained.
59. Apparatus as claimed in claim 58, including means for applying a narrow ultrasound reference beam within said region, said reference beam having a known CSA (CSAref), and means for computing Flow CSA from Flow CSA=CSAref·PImeas/PIref.
60. Apparatus as claimed in claim 59, wherein said flow is regurgitant flow through a faulty heart valve, and including means for detecting Doppler ultrasound power from said reference beam when the valve is open for forward flow.
61. Apparatus for obtaining flow rate of blood passing through a dynamic orifice in at least one direction including:
a) means for ensonifying a sample volume of blood flow exiting the orifice, which volume is in a region of said flow which is substantially laminar, with an ultrasonic pulsed Doppler signal;
b) a receiver for backscattered signal from blood within said sample volume;
c) means for forming a power-velocity spectrum from received backscattered signal; and
d) means for forming the instantaneous power-velocity integral for laminar flow of the power-velocity spectrum as the integral of power times velocity, said power-velocity integral being proportional to instantaneous flow rate of the laminar flow.
62. Apparatus as claimed in claim 61, including means for identifying a narrow velocity spectrum of laminar flow to be used in the power-velocity integral calculation, said means including:
(a) means for smoothing the power-velocity spectrum;
(b) means for determining the velocity of peak power in a smoothed power-velocity spectrum;
(c) means for determining a lower velocity of laminar flow, said lower velocity being a selected velocity less than the velocity for peak power where the power is a specified percentage of the peak power; and
(d) means for determining an upper velocity of laminar flow, said upper velocity being a selected velocity greater than the velocity of peak power where the power is a specified percentage of the peak power.
63. Apparatus as claimed in claim 61, wherein said sample volume is at the vena contracta of flow exiting the orifice.
64. Apparatus as claimed in claim 63, including means for steering and focusing the ultrasonic signal to said vena contracta.
65. Apparatus as claimed in claim 61, wherein said ultrasonic signal to be used for said power-velocity integral measurement (PVImeas) is wide enough to fully ensonify the cross-sectional area of the laminar flow.
66. Apparatus as claimed in claim 61, including means for obtaining a profile of instantaneous flow rates over time by successively operating means a), b), c) and d).
67. Apparatus as claimed in claim 61, wherein said flow is regurgitant flow though a faulty heart valve, the flow rate being that passing through lesion in the heart valve permitting the regurgitant flow.
68. Apparatus as claimed in claim 61, wherein said flow is stenotic flow through a restricted heart valve, the flow rate being that passing through the restricted valve opening area permitting the flow in normal direction through the valve.
69. Apparatus as claimed in claim 61, wherein said flow is shunt flow through a shunt lesion, the flow rate being that passing through shunt lesions permitting the shunt flow.
70. Apparatus method as claimed in claim 61, wherein said flow is stenotic flow through a restricted peripheral vessel, the flow rate being that passing through the restricted area of flow.
71. Apparatus method as claimed in claim 61, including means for calibrating to permit absolute flow rate to be obtained.
72. Apparatus as claimed in claim 71, including means for applying a narrow ultrasound reference beam within said region, said reference beam having a known CSA (CSAref), and computing Flow rate from Flow rate=CSAref·PVImeas/PIref.
73. Apparatus as claimed in claim 72, wherein said flow is regurgitant flow through a faulty heart valve, and including means for detecting Doppler ultrasound power from said reference beam when the valve is open for forward flow.
74. A method as claimed in claim 61, wherein said pulsed wave Doppler signal is a high-PRF Doppler signal.
75. Apparatus for obtaining flow volume of blood passing through a dynamic orifice in at least one direction including:
a) means for ensonifying a sample volume of blood flow exiting the orifice, which volume is in a region of said flow which is substantially laminar, with an ultrasonic pulsed Doppler signal;
b) means for receiving backscattered signal from blood within said sample volume;
c) means for forming a power-velocity spectrum from received backscattered signal;
d) means for forming the instantaneous integral of power times velocity for laminar flow of the power-velocity spectrum;
e) means for obtaining a time profile of the instantaneous flow rate by successively operating means a) through d); and
f) means for obtaining the time integral of the instantaneous flow rate profile for that interval of time where flow volume is to be measured, said time integral of instantaneous power-velocity integrals being proportional to flow volume.
76. Apparatus as claimed in claim 75, including means for identifying a narrow velocity spectrum of laminar flow to be used in the power integral calculation, said means including:
(a) means for smoothing the power-velocity spectrum;
(b) means for determining the velocity of peak power in a smoothed power-velocity spectrum;
(c) means for determining a lower velocity of laminar flow, said lower velocity being a selected velocity less than the velocity for peak power where the power is a specified percentage of the peak power; and
(d) means for determining an upper velocity of laminar flow, said upper velocity being a selected velocity greater than the velocity of peak power where the power is a specified percentage of the peak power.
77. Apparatus as claimed in claim 75, wherein said sample volume is at the vena contracta of flow exiting the orifice.
78. Apparatus as claimed in claim 77, including means for steering and focusing the ultrasonic signal to said vena contracta.
79. Apparatus as claimed in claim 75, wherein said ultrasonic signal to be used for said power-velocity time integral measurement (PVTImeas) is wide enough to fully ensonify the cross-sectional area of the laminar flow.
80. Apparatus as claimed in claim 75, wherein said flow is regurgitant flow though a faulty heart valve, the flow rate being that passing through lesion in the heart valve permitting the regurgitant flow.
81. Apparatus as claimed in claim 75, wherein said flow is stenotic flow through a restricted heart valve, the flow volume being that passing through the restricted valve opening area permitting the flow in normal direction through the valve.
82. Apparatus as claimed in claim 75, wherein said flow is shunt flow through a shunt lesion, the flow volume being that passing through shunt lesions permitting the shunt flow.
83. Apparatus as claimed in claim 75, wherein said flow is stenotic flow through a restricted peripheral vessel, the flow volume being that passing through the restricted area of flow.
84. Apparatus as claimed in claim 75, including means for calibrating to permit absolute flow volume to be obtained.
85. Apparatus as claimed in claim 84, including means for applying a narrow ultrasound reference beam within said region, said reference beam having a known CSA (CSAref), and computing Flow volume from Flow volume=CSAref·PVTImeas/PIref.
86. Apparatus as claimed in claim 85, wherein said flow is regurgitant flow through a faulty heart valve, and including means for detecting Doppler ultrasound power from said reference beam when the valve is open for forward flow.
87. Apparatus as claimed in claim 86, including means for determining cardiac output, said means including:
(i) means for measuring blood flow volume passing through a heart valve orifice in the forward direction;
(ii) means for measuring regurgitant blood flow volume passing through said heart valve orifice in the reverse direction; and
(iii) means for summing the measurements of (i) and (ii) so as to provide a measure of the cardiac output.
88. Apparatus as claimed in claim 80, including means for computing the fraction of reverse versus forward flow, said means including:
(i) means for uncalibrated measurement of blood flow volume passing through the orifice in the forward direction;
(ii) means for uncalibrated measurement of regurgitant blood flow volume passing through the orifice in the reverse direction; and
(iii) means for combining the measurements of (i) and (ii) so as to provide a measure of the regurgitant fraction.
89. A method as claimed in claim 75, wherein said pulsed wave Doppler signal is a high-PRF Doppler signal.
US09/467,165 1999-03-05 1999-12-20 Method and apparatus for measuring volume flow and area for a dynamic orifice Expired - Fee Related US6544181B1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US09/467,165 US6544181B1 (en) 1999-03-05 1999-12-20 Method and apparatus for measuring volume flow and area for a dynamic orifice
PCT/US2000/004303 WO2000051495A1 (en) 1999-03-05 2000-02-18 Measuring volume flow and area for a dynamic orifice
CA002362628A CA2362628A1 (en) 1999-03-05 2000-02-18 Measuring volume flow and area for a dynamic orifice
EP00921337A EP1161180A1 (en) 1999-03-05 2000-02-18 Measuring volume flow and area for a dynamic orifice
US10/303,252 US20030109785A1 (en) 1999-03-05 2002-11-25 Method and apparatus for measuring volume flow and area for a dynamic orifice

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12292699P 1999-03-05 1999-03-05
US09/467,165 US6544181B1 (en) 1999-03-05 1999-12-20 Method and apparatus for measuring volume flow and area for a dynamic orifice

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/303,252 Continuation US20030109785A1 (en) 1999-03-05 2002-11-25 Method and apparatus for measuring volume flow and area for a dynamic orifice

Publications (2)

Publication Number Publication Date
US20030055336A1 true US20030055336A1 (en) 2003-03-20
US6544181B1 US6544181B1 (en) 2003-04-08

Family

ID=26821019

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/467,165 Expired - Fee Related US6544181B1 (en) 1999-03-05 1999-12-20 Method and apparatus for measuring volume flow and area for a dynamic orifice
US10/303,252 Abandoned US20030109785A1 (en) 1999-03-05 2002-11-25 Method and apparatus for measuring volume flow and area for a dynamic orifice

Family Applications After (1)

Application Number Title Priority Date Filing Date
US10/303,252 Abandoned US20030109785A1 (en) 1999-03-05 2002-11-25 Method and apparatus for measuring volume flow and area for a dynamic orifice

Country Status (4)

Country Link
US (2) US6544181B1 (en)
EP (1) EP1161180A1 (en)
CA (1) CA2362628A1 (en)
WO (1) WO2000051495A1 (en)

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127797A1 (en) * 2002-06-07 2004-07-01 Bill Barnard System and method for measuring bladder wall thickness and presenting a bladder virtual image
US20050148874A1 (en) * 2003-12-19 2005-07-07 Brock-Fisher George A. Ultrasonic imaging aberration correction with microbeamforming
US20050215896A1 (en) * 2002-08-09 2005-09-29 Mcmorrow Gerald Instantaneous ultrasonic echo measurement of bladder volume with a limited number of ultrasound beams
US20060025689A1 (en) * 2002-06-07 2006-02-02 Vikram Chalana System and method to measure cardiac ejection fraction
US20060058675A1 (en) * 2004-08-31 2006-03-16 General Electric Company Three dimensional atrium-ventricle plane detection
US20070232908A1 (en) * 2002-06-07 2007-10-04 Yanwei Wang Systems and methods to improve clarity in ultrasound images
US20070276254A1 (en) * 2002-06-07 2007-11-29 Fuxing Yang System and method to identify and measure organ wall boundaries
US20080242985A1 (en) * 2003-05-20 2008-10-02 Vikram Chalana 3d ultrasound-based instrument for non-invasive measurement of amniotic fluid volume
US20080262356A1 (en) * 2002-06-07 2008-10-23 Vikram Chalana Systems and methods for ultrasound imaging using an inertial reference unit
US20090062644A1 (en) * 2002-06-07 2009-03-05 Mcmorrow Gerald System and method for ultrasound harmonic imaging
US20090112089A1 (en) * 2007-10-27 2009-04-30 Bill Barnard System and method for measuring bladder wall thickness and presenting a bladder virtual image
US20090264757A1 (en) * 2007-05-16 2009-10-22 Fuxing Yang System and method for bladder detection using harmonic imaging
US20090270980A1 (en) * 2000-10-06 2009-10-29 Edwards Lifesciences Llc Methods and Devices for Improving Mitral Valve Function
US20100006649A1 (en) * 2008-07-11 2010-01-14 Steve Bolton Secure Ballot Box
US20100036252A1 (en) * 2002-06-07 2010-02-11 Vikram Chalana Ultrasound system and method for measuring bladder wall thickness and mass
US20100036242A1 (en) * 2007-05-16 2010-02-11 Jongtae Yuk Device, system and method to measure abdominal aortic aneurysm diameter
US8221321B2 (en) 2002-06-07 2012-07-17 Verathon Inc. Systems and methods for quantification and classification of fluids in human cavities in ultrasound images
US20120215110A1 (en) * 2011-02-23 2012-08-23 Siemens Medical Solutions Usa, Inc. Multiple Beam Spectral Doppler in Medical Diagnostic Ultrasound Imaging
US20150087980A1 (en) * 2012-06-05 2015-03-26 Kabushiki Kaisha Toshiba Ultrasound diagnosis apparatus and image processing apparatus
US20160157826A1 (en) * 2013-07-24 2016-06-09 Koninklijke Philips N.V. Non-imaging two dimensional array probe and system for automated screening of carotid stenosis
CN111343923A (en) * 2017-11-13 2020-06-26 爱德华兹生命科学公司 Non-invasive heart valve screening device and method
US11147531B2 (en) * 2015-08-12 2021-10-19 Sonetics Ultrasound, Inc. Method and system for measuring blood pressure using ultrasound by emitting push pulse to a blood vessel
WO2022099698A1 (en) * 2020-11-16 2022-05-19 深圳迈瑞生物医疗电子股份有限公司 Ultrasound imaging system and method, and computer storage medium

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6149595A (en) * 1998-07-02 2000-11-21 Seitz; Walter S. Noninvasive apparatus and method for the determination of cardiac valve function
US6544181B1 (en) 1999-03-05 2003-04-08 The General Hospital Corporation Method and apparatus for measuring volume flow and area for a dynamic orifice
US7534209B2 (en) * 2000-05-26 2009-05-19 Physiosonics, Inc. Device and method for mapping and tracking blood flow and determining parameters of blood flow
US7399279B2 (en) * 1999-05-28 2008-07-15 Physiosonics, Inc Transmitter patterns for multi beam reception
US6915152B2 (en) * 2001-04-19 2005-07-05 General Electric Company Method for MR imaging with an array of RF coils
EP1511974B1 (en) 2002-02-27 2016-08-10 Esaote S.p.A. Flow-rate conservative doppler estimate
US7024244B2 (en) 2002-04-22 2006-04-04 Medtronic, Inc. Estimation of stroke volume cardiac output using an intracardiac pressure sensor
WO2004075754A1 (en) * 2003-02-27 2004-09-10 Universität Duisburg-Essen Method and device for ultrasound measurement of blood flow
DE10312883B4 (en) * 2003-02-27 2007-02-22 Universität Duisburg-Essen Method and apparatus for ultrasonic measurement
US20040186381A1 (en) * 2003-03-20 2004-09-23 Siemens Medical Solutions Usa, Inc. Volume flow rate with medical ultrasound imaging
CN100446733C (en) * 2003-07-22 2008-12-31 株式会社日立医药 Ultrasonographic device and ultrasonographic method
US7903902B2 (en) * 2004-07-26 2011-03-08 Sheraizin Semion M Adaptive image improvement
US8214168B2 (en) * 2004-09-07 2012-07-03 Transonic Systems, Inc. Noninvasive testing of a material intermediate spaced walls
US7044922B1 (en) 2004-12-29 2006-05-16 Leon Michael Dondysh Non-invasive diagnostic apparatus and method comprising a cerebral stethoscope for detecting cerebrovascular disease
US9204819B2 (en) 2005-05-06 2015-12-08 Vasonova, Inc. Endovenous access and guidance system utilizing non-image based ultrasound
US8597193B2 (en) 2005-05-06 2013-12-03 Vasonova, Inc. Apparatus and method for endovascular device guiding and positioning using physiological parameters
US20090118612A1 (en) 2005-05-06 2009-05-07 Sorin Grunwald Apparatus and Method for Vascular Access
US20070073152A1 (en) * 2005-09-13 2007-03-29 General Electric Company Systems and methods for acquiring images simultaneously
US20070167751A1 (en) * 2005-12-05 2007-07-19 Schilling Ronald B Method and apparatus for vessel characterization
US8070684B2 (en) * 2005-12-14 2011-12-06 St. Jude Medical, Atrial Fibrillation Division, Inc. Method and system for evaluating valvular function
RU2008134879A (en) * 2006-01-27 2010-03-10 Конинклейке Филипс Электроникс Н.В. (Nl) AUTOMATED ULTRASONIC DOPLER MEASUREMENTS
DE202008003245U1 (en) 2007-02-21 2008-06-05 Universität Duisburg-Essen Apparatus for ultrasonic measurement of blood flow
US20090043208A1 (en) * 2007-08-10 2009-02-12 Norwegian University Of Science And Technology Methods and devices for estimating blood flow characteristics
US8273029B2 (en) * 2008-02-18 2012-09-25 Washington University Pressure recovery index to assess cardiac function
US9405996B2 (en) * 2008-09-18 2016-08-02 Siemens Aktiengesellschaft Method and system for generating a personalized anatomical heart model
SE536017C2 (en) * 2010-10-12 2013-04-02 Braennstroem Gruppen Ab Method and apparatus for indicating a fluid flow
EP2637568B1 (en) 2010-11-08 2017-04-12 Vasonova, Inc. Endovascular navigation system
WO2012131340A2 (en) 2011-03-25 2012-10-04 Norwegian University Of Science And Technology (Ntnu) Methods and apparatus for multibeam doppler ultrasound display
US10311978B2 (en) * 2012-01-30 2019-06-04 Siemens Healthcare Gmbh Method and system for patient specific planning of cardiac therapies on preoperative clinical data and medical images
US9345447B2 (en) 2012-05-07 2016-05-24 Vasonova, Inc. Right atrium indicator
US10154826B2 (en) 2013-07-17 2018-12-18 Tissue Differentiation Intelligence, Llc Device and method for identifying anatomical structures
US10716536B2 (en) 2013-07-17 2020-07-21 Tissue Differentiation Intelligence, Llc Identifying anatomical structures
US11701086B1 (en) 2016-06-21 2023-07-18 Tissue Differentiation Intelligence, Llc Methods and systems for improved nerve detection
US11517287B2 (en) 2017-03-07 2022-12-06 The University Of Tokyo Tissue elasticity measurement device and measurement method
US10835201B2 (en) 2017-10-31 2020-11-17 Edwards Lifesciences Corporation Non-invasive wearable heart valve monitor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4259870A (en) * 1979-02-26 1981-04-07 Howmedica Inc. Doppler method of measuring flow
US4807636A (en) * 1986-09-09 1989-02-28 Vital Science Corporation Method and apparatus for measuring volume fluid flow
US5062427A (en) 1988-05-06 1991-11-05 Kabushiki Kaisha Toshiba Ultrasonic doppler apparatus
US5390677A (en) 1994-05-31 1995-02-21 The Regents Of The University Of California Method for assessing and displaying the true three dimensional magnitude of blood velocity
US6544181B1 (en) 1999-03-05 2003-04-08 The General Hospital Corporation Method and apparatus for measuring volume flow and area for a dynamic orifice

Cited By (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090270980A1 (en) * 2000-10-06 2009-10-29 Edwards Lifesciences Llc Methods and Devices for Improving Mitral Valve Function
US9198757B2 (en) * 2000-10-06 2015-12-01 Edwards Lifesciences, Llc Methods and devices for improving mitral valve function
US8221321B2 (en) 2002-06-07 2012-07-17 Verathon Inc. Systems and methods for quantification and classification of fluids in human cavities in ultrasound images
US20060025689A1 (en) * 2002-06-07 2006-02-02 Vikram Chalana System and method to measure cardiac ejection fraction
US8221322B2 (en) 2002-06-07 2012-07-17 Verathon Inc. Systems and methods to improve clarity in ultrasound images
US20070232908A1 (en) * 2002-06-07 2007-10-04 Yanwei Wang Systems and methods to improve clarity in ultrasound images
US20070276254A1 (en) * 2002-06-07 2007-11-29 Fuxing Yang System and method to identify and measure organ wall boundaries
US7819806B2 (en) 2002-06-07 2010-10-26 Verathon Inc. System and method to identify and measure organ wall boundaries
US20080262356A1 (en) * 2002-06-07 2008-10-23 Vikram Chalana Systems and methods for ultrasound imaging using an inertial reference unit
US20090062644A1 (en) * 2002-06-07 2009-03-05 Mcmorrow Gerald System and method for ultrasound harmonic imaging
US20040127797A1 (en) * 2002-06-07 2004-07-01 Bill Barnard System and method for measuring bladder wall thickness and presenting a bladder virtual image
US20100036252A1 (en) * 2002-06-07 2010-02-11 Vikram Chalana Ultrasound system and method for measuring bladder wall thickness and mass
US7749165B2 (en) * 2002-08-09 2010-07-06 Verathon Inc. Instantaneous ultrasonic echo measurement of bladder volume with a limited number of ultrasound beams
US9993225B2 (en) * 2002-08-09 2018-06-12 Verathon Inc. Instantaneous ultrasonic echo measurement of bladder volume with a limited number of ultrasound beams
US8308644B2 (en) 2002-08-09 2012-11-13 Verathon Inc. Instantaneous ultrasonic measurement of bladder volume
US20050215896A1 (en) * 2002-08-09 2005-09-29 Mcmorrow Gerald Instantaneous ultrasonic echo measurement of bladder volume with a limited number of ultrasound beams
US20100198075A1 (en) * 2002-08-09 2010-08-05 Verathon Inc. Instantaneous ultrasonic echo measurement of bladder volume with a limited number of ultrasound beams
US20080242985A1 (en) * 2003-05-20 2008-10-02 Vikram Chalana 3d ultrasound-based instrument for non-invasive measurement of amniotic fluid volume
US20050148874A1 (en) * 2003-12-19 2005-07-07 Brock-Fisher George A. Ultrasonic imaging aberration correction with microbeamforming
US20060058675A1 (en) * 2004-08-31 2006-03-16 General Electric Company Three dimensional atrium-ventricle plane detection
US8133181B2 (en) 2007-05-16 2012-03-13 Verathon Inc. Device, system and method to measure abdominal aortic aneurysm diameter
US8167803B2 (en) 2007-05-16 2012-05-01 Verathon Inc. System and method for bladder detection using harmonic imaging
US20100036242A1 (en) * 2007-05-16 2010-02-11 Jongtae Yuk Device, system and method to measure abdominal aortic aneurysm diameter
US20090264757A1 (en) * 2007-05-16 2009-10-22 Fuxing Yang System and method for bladder detection using harmonic imaging
US20090112089A1 (en) * 2007-10-27 2009-04-30 Bill Barnard System and method for measuring bladder wall thickness and presenting a bladder virtual image
US20100006649A1 (en) * 2008-07-11 2010-01-14 Steve Bolton Secure Ballot Box
US20120215110A1 (en) * 2011-02-23 2012-08-23 Siemens Medical Solutions Usa, Inc. Multiple Beam Spectral Doppler in Medical Diagnostic Ultrasound Imaging
US9398898B2 (en) * 2011-02-23 2016-07-26 Siemens Medical Solutions Usa, Inc. Multiple beam spectral doppler in medical diagnostic ultrasound imaging
US20150087980A1 (en) * 2012-06-05 2015-03-26 Kabushiki Kaisha Toshiba Ultrasound diagnosis apparatus and image processing apparatus
US11672506B2 (en) * 2012-06-05 2023-06-13 Canon Medical Systems Corporation Ultrasound diagnosis apparatus and image processing apparatus
US20160157826A1 (en) * 2013-07-24 2016-06-09 Koninklijke Philips N.V. Non-imaging two dimensional array probe and system for automated screening of carotid stenosis
US11090029B2 (en) * 2013-07-24 2021-08-17 Koninklijke Philips N.V. System for automated screening of carotid stenosis
US11147531B2 (en) * 2015-08-12 2021-10-19 Sonetics Ultrasound, Inc. Method and system for measuring blood pressure using ultrasound by emitting push pulse to a blood vessel
CN111343923A (en) * 2017-11-13 2020-06-26 爱德华兹生命科学公司 Non-invasive heart valve screening device and method
WO2022099698A1 (en) * 2020-11-16 2022-05-19 深圳迈瑞生物医疗电子股份有限公司 Ultrasound imaging system and method, and computer storage medium

Also Published As

Publication number Publication date
US20030109785A1 (en) 2003-06-12
WO2000051495A1 (en) 2000-09-08
WO2000051495A9 (en) 2001-10-25
US6544181B1 (en) 2003-04-08
EP1161180A1 (en) 2001-12-12
CA2362628A1 (en) 2000-09-08

Similar Documents

Publication Publication Date Title
US6544181B1 (en) Method and apparatus for measuring volume flow and area for a dynamic orifice
Stewart et al. Variable effects of changes in flow rate through the aortic, pulmonary and mitral valves on valve area and flow velocity: impact on quantitative Doppler flow calculations
US9320496B2 (en) Volumetric is quantification for ultrasound diagnostic imaging
US20130245441A1 (en) Pressure-Volume with Medical Diagnostic Ultrasound Imaging
Gardin et al. Superiority of two-dimensional measurement of aortic vessel diameter in Doppler echocardiographic estimates of left ventricular stroke volume
US20170325770A1 (en) Methods for personalizing blood flow models
Prinz et al. Can echocardiographic particle image velocimetry correctly detect motion patterns as they occur in blood inside heart chambers? A validation study using moving phantoms
WO2006129545A1 (en) Ultrasonograph
Brubakk et al. Diagnosis of valvular heart disease using transcutaneous Doppler ultrasound
Zhang et al. Doppler echocardiographic measurement of cardiac output using the mitral orifice method.
Buck et al. The power-velocity integral at the vena contracta: a new method for direct quantification of regurgitant volume flow
Valdes-Cruz et al. Studies in vitro of the relationship between ultrasound and laser Doppler velocimetry and applicability to the simplified Bernoulli relationship.
Fraser et al. Ultrasound imaging velocimetry with interleaved images for improved pulsatile arterial flow measurements: a new correction method, experimental and in vivo validation
Gudmundsson et al. Factors affecting color Doppler energy ultrasound recordings in an in-vitro model
US8070684B2 (en) Method and system for evaluating valvular function
Buck et al. Flow quantification in valvular heart disease based on the integral of backscattered acoustic power using Doppler ultrasound
Shiota et al. Color flow Doppler determination of transmitral flow and orifice area in mitral stenosis: experimental evaluation of the proximal flow-convergence method
JP2022515087A (en) Methods and systems for obtaining physiological measures from subjects
Hoit et al. Calculating cardiac output from transmitral volume flow using Doppler and M-mode echocardiography
Naqvi et al. Aortic stenosis: the role of transesophageal echocardiography
Bednarz et al. An echocardiographic approach to the assessment of aortic stenosis
Shiota et al. Evaluation of aortic regurgitation with digitally determined color Doppler-imaged flow convergence acceleration: a quantitative study in sheep
WO2010147055A1 (en) Ultrasonic image pickup apparatus and ultrasonic image pickup method
WO2021058339A1 (en) Methods and systems for modeling a cardiac system
KR20210112807A (en) Ultrasound image apparatus and method for controlling thereof

Legal Events

Date Code Title Description
AS Assignment

Owner name: AGILENT TECHNOLOGIES, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MUCCI, RONALD A.;REEL/FRAME:012761/0687

Effective date: 20010710

Owner name: THE GENERAL HOSPITAL CORPORATION A MASSACHUSETTS C

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BUCK, THOMAS;REEL/FRAME:012764/0442

Effective date: 20010719

AS Assignment

Owner name: GENERAL HOSPITAL CORPORATION, THE, MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LEVINE, ROBERT A.;REEL/FRAME:013039/0451

Effective date: 20020506

AS Assignment

Owner name: AGILENT TECHNOLOGIES INC., COLORADO

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HEWLETT-PACKARD COMPANY;REEL/FRAME:013404/0080

Effective date: 20021002

AS Assignment

Owner name: KONINKLIJKE PHILIPS ELECTRONICS N.V., NETHERLANDS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:AGILENT TECHNOLOGIES INC.;REEL/FRAME:013531/0838

Effective date: 20010801

FPAY Fee payment

Year of fee payment: 4

FEPP Fee payment procedure

Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

AS Assignment

Owner name: KONINKLIJKE PHILIPS ELECTRONICS N V, NETHERLANDS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:AGILENT TECHNOLOGIES, INC.;REEL/FRAME:022835/0572

Effective date: 20090610

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20110408

AS Assignment

Owner name: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR, MA

Free format text: CONFIRMATORY LICENSE;ASSIGNOR:PARTNERS HEALTHCARE INNOVATION;REEL/FRAME:042684/0945

Effective date: 20170613